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FORMAL REMARKS
Formal remarks
In accordance with the common practice in English scientific writing, the present manuscript
is partially written in the first-person plural narrative.
Official murine gene and protein symbols in this manuscript were formatted according to
the guidelines of "The Journal of Clinical Investigation":
 Genes, mRNA and genotypes: italicized, first letter capitalized (e. g. Cers2gt/gt mice)
 Proteins: non-italicized, capitalized (e. g. CERS2)
Some of the results that are shown in the present manuscript have already been published
in a peer-reviewed journal with me as lead author [1]. The respective parts are highlighted
in the figure legends.
The mass spectrometric measurements that are shown in this manuscript (Figure 4.9, 4.12,
4.13 and 4.16) were performed by Prof. Dr.Markus Gräler on a collaborative basis (De-
partment of Anesthesiology and Intensive Care Medicine, Center for Sepsis Control and
Care (CSCC), and the Center for Molecular Biomedicine (CMB), Jena University Hospital,
Jena, Germany).
The generation of bone marrow chimeras, as well as the transplantation of thymic lobes
under the kidney capsule of recipient mice (see 4.2.1 and 4.2.2) were performed in col-
laboration with the laboratory of Prof. Dr. Christian Kurts (Institute for Experimental
Immunology, University Hospital Bonn, Germany). The analyses of chimeric mice and
thymic grafts were completely conducted by myself.
Mice of the Cers2gt and the Cers4Δneo lines (see 3.1.10) were a kind gift from the lab of
Prof. Dr.Klaus Willecke (Molecular Genetics & Cell Biology, Life and Medical Sciences
Institute, University of Bonn, Bonn, Germany). Husbandry of Cers2gt mice was organized
by myself. Breeding of Cers4Δneo mice remained under the control of the group of Prof.
Willecke.
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1 INTRODUCTION
1 Introduction
1.1 T cell-mediated immunity
In the course of evolution, metazoan organisms developed complex strategies and mech-
anisms, collectively called immune system, to protect themselves from infections with
pathogens. In mammals and most other vertebrates, the immune system can be subdi-
vided into the innate immune system and the adaptive immune system [2, 3, 4]. Whereas
the innate immune system is based on the detection of evolutionary broadly conserved
structures of microbial or viral origin, collectively termed PAMPs (pathogen-associated
molecular patterns), such as LPS (lipopolysaccharide) from Gram-negative bacteria or
dsRNA (double-stranded DNA) from certain viruses, the adaptive immune system induces
immune responses that are highly specific for individual pathogens [3, 5]. Adaptive im-
mune responses are mediated by lymphocytes, which can be subdivided into B and T
cells. Specific somatic recombination mechanisms, which randomly rearrange a certain set
of gene segments during lymphocyte development, lead to the expression of a unique and
highly specific antigen receptor on each B and T cell (BCR = B cell receptor and TCR
= T cell receptor) [6, 7]. Therefore, only few cells of the whole lymphocyte pool are able
to detect the presence of a given pathogen. However, those cells that are stimulated by
a cognate interaction between their antigen receptor and an invading pathogen undergo
massive clonal expansion and differentiate into effector cells to induce a highly specific
immune response [3].
Effector B cells (plasma cells or ASCs (antibody-secreting cells)) secrete large amounts of
antibodies, which represent the soluble form of their BCR, recognizing the same antigen
by which the original B cell was activated [8]. Antibodies bind and cross-link their target
structures, causing their inactivation, e.g. in the case of a soluble toxin, and/or their
endocytosis by professional phagocytes of the innate immune system, e.g. in the case of a
pathogenic bacterium [3].
T cells can be subdivided into CD8+ T cells that differentiate into effector cytotoxic T
lymphocytes (CTLs) and CD4+ T cells that differentiate into effector T helper (TH) cells
upon activation [3, 9]. CTLs propagate local inflammatory responses by releasing type 1
cytokines, such as TNF-a or IFN-g, and eliminate intracellularly infected host cells by the
directed release of cytotoxic granules, containing granzyme B or perforin [3, 10, 11, 12, 13].
In contrast to CD8+ T cells, CD4+ T cells can differentiate into several distinct effector
subtypes (TH1, TH2, TH9, TH17, TFH or TReg), which contribute to immune responses by
different mechanisms, such as licensing the activation of innate immune cells or supporting
antibody production by B cells. The polarization into the respective subtypes is mainly
driven by the cytokine environment and partially by the strength of TCR stimulation. As
infections with different pathogens induce specific cytokine profiles, fate determination of
naive CD4+ T cells into the specific effector subsets is a direct and specific response to
particular pathogens. Thus, the organism promotes production of those TH subsets that
1
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are capable of supporting an appropriate and customized immune response to the invading
pathogen [14].
Under homeostatic, non-infected conditions, resting (non-activated) CD4+ and CD8+ T
cells patrol constantly through blood, lymph nodes, lymphatics and spleen in a process
termed lymphocyte circulation. With regard to the small number of lymphocytes whose
receptor is specific for a given antigen, their continuous recirculation drastically increases
the chance of detecting cognate antigens on antigen-presenting cells (APCs), such as DCs
(dendritic cells), which transport pathogenic material from all peripheral tissues into the
lymph nodes [3, 15, 16]. After 8 - 12 hours without cognate interaction, T cells leave
the lymph nodes via the efferent lymphatics and re-enter the blood through the thoracic
duct [15]. Upon a cognate interaction, however, T cells stay in the lymph nodes until their
differentiation into effector cells is completed and they have performed several rounds of
cell division. As fully differentiated effector T cells, they leave the lymph node and travel
to the site of infection, where they participate in the (local) battle against the infectious
agents [3, 17]. After successful clearance of invading pathogens, most effector T cells die
by apoptosis, except for a small group that differentiates into memory T cells and thus
provides long-term protection. In case of a second infection with an already encountered
pathogen, cognate memory cells can induce an adaptive immune response, which is faster
and more efficient than the mechanisms upon the first encounter [18].
1.2 Thymic T cell development
At a given time, the peripheral T cell pool of a human, which contains approximately
1011 naive T cells, comprises at least 108 unique TCR specificities, enabling the induction
of adaptive immune responses against a broad spectrum of different pathogens [19]. This
enormous diversity is the result of special genomic recombination mechanisms, which ran-
domly rearrange the coding sequences of the TCRs during T cell development. Each TCR
is a heterodimer, composed of an α and a β chain. Both chains contain an invariant and a
variable domain. While the invariant domains anchor the TCR in the plasma membrane
and interact with cytosolic and other membrane-bound effectors, the variable domains ex-
tent into the extracellular space and form the antigen binding site. The variable domains
of α and β chains are genetically encoded by special gene segments, termed V (variable),
D (diversity) and J (joining) segments. In germline configuration, the locus of an α chain
contains 70 V and 61 J segments, whereas the locus of a β chain contains 52 V, 2 D and 13 J
segments. During T cell development, however, these segments are randomly rearranged in
a regulated process called V(D)J recombination. As each segment has a unique sequence
and both chains are independently recombined, a large number of TCRs with different
antigen specificities is generated. This diversity is even more increased by the addition or
removal of single nucleotides at the junctions between the segments. Taken together, the
theoretical number of different TCRs is larger than 1018 [3, 6, 20, 21]. However, the gener-
ation of TCRs by stochastic means is a two-edged sword, as it accidentally produces TCRs
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that are either non-functional or reactive to self antigens. To prevent immunosuppression
on the one side and severe autoimmune reactions on the other side, those inoperative and
autoreactive TCRs must be rapidly eliminated from the TCR pool. Consequently, T cell
development comprises not only the steps that regulate antigen receptor diversification, but
also various mechanisms which ensure that only the cells with functional and self-tolerant
TCRs complete their differentiation and become part of the peripheral T cell pool [22]. T
cell development is located in the thymus, which provides a unique microenvironment for
efficient TCR recombination and the subsequent selection procedures [3, 23].
1.2.1 Thymus anatomy
The thymus is a two-lobed primary lymphoid organ, which is located within the thoracic
cavity. Both lobes are of comparable size and have identical functions. The thymus is
surrounded by a collagenous capsule, which occasionally extends into the organ, forming
trabeculae, which subdivide the lobes into several smaller lobules. Each lobule consists of
an outer cortex and an inner medulla, which have contact at the corticomedullary junction
(CMJ). The cortex, especially the zone close to the capsule (subcapsular zone (SCZ)), is the
area of early T cell differentiation, TCR rearrangement and positive selection of functional
TCRs. Besides a high number of developing T cells, the cortex is characterized by the
presence cTECs (cortical thymic epithelial cells), which mediate positive selection. The
medulla is the area of negative selection of TCRs that recognize self-antigens. Harboring
fewer developing T cells than the cortex, the medulla can be identified by the presence
of mTECs, which mediate negative selection. The corticomedullary junction contains
blood vessels, through which hematopoietic progenitors enter the thymus and terminally
differentiated T cells emigrate into the circulation [3, 24, 25, 26]. Worthy of note is that the
thymus size is dependent on the age of the organism. After reaching its maximal size at
adolescence, the thymus involutes constantly by reducing the cortical and medullary mass,
as well as by incorporating fat tissue. Thymus involution is accompanied by a reduced T
cell output [27, 28].
1.2.2 The stages of T cell development
The development of hematopoietic precursors into T cells can be subdivided into several
stages (Figure 1.1). As the developmental processes in each stage require a distinct mi-
croenvironment, involving e.g. intercellular contacts to specific stromal cells, developing
T cells travel sequentially through the discrete areas of the thymus in the course of their
differentiation. Starting at the CMJ, developing T cells migrate through the cortex into
the SCZ, from which they head to the medulla, before they travel back to the CMJ, where
they eventually emigrate into the periphery. The stages of development can be identified
by the expression of specific marker molecules (e.g. CD4, CD8, CD25, CD44, CD117, etc.
. . . ) on the surface of the developing T cells. Whereas the late stages can be characterized
3
1 INTRODUCTION
by the differential expression of CD4 and CD8 (DP = double positive, CD4SP and CD8SP
= CD4 and CD8 single positive), the early stage is marked by the absence of CD4 and
CD8 (DN = double negative). However, the DN stage can be further subdivided into four
large fractions (DN1  DN4) on the basis of different expression patterns of CD25 and
CD44 (DN1 = CD25-/CD44+, DN2 = CD25+/CD44+, DN3 = CD25+/CD44- and DN4
= CD25-/CD44-) [24, 29].
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Figure 1.1: Overview of T cell development in the thymus. The layout of this figure is based on the
graphics of [24, 25].
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T cell development begins at the CMJ, where bone marrow-derived TSPs (thymic seed-
ing progenitors) enter the thymus, differentiate into ETPs (early thymic progenitors)
upon the contact with thymic stroma cells and become thus part of the DN1 subset
(CD4-/CD8-/CD25-/CD44+), which represents the earliest stage of T cell development [30].
The cells of the DN1 subset proliferate extensively and become more committed to the T
cell line via Notch1-DLL4 signaling. After approximately 10 days of proliferation, DN1
cells leave the CMJ and migrate into the cortex, while progressing into the DN2 stage
(CD4-/CD8-/CD25+/CD44+) [31, 32, 33, 34]. Besides further commitment to the T cell
lineage, most DN2 thymocytes begin to diversify their TCR by rearranging the VDJ seg-
ments of the β chain locus [35, 36]. Worthy of note is that a small DN2 thymocyte popu-
lation, which is characterized by a high expression of IL7R, recombines the alternative γ
and δ TCR chains, instead of the β chain. Those cells give rise to the non-canonical γδ T
cells, a divergent tissue-associated T cell subset with special functions, which, for instance,
forms a large fraction of the IELs (intraepithelial lymphocytes) in the gut [37, 38, 39]. The
transition from the DN2 to the DN3 (CD4-/CD8-/CD25+/CD44-) stage occurs in the SCZ.
In the DN3 stage, the success of the β chain recombination is monitored in a process termed
β-selection. While the developing T cells intensively rearrange their β chain, they begin to
express an invariant surrogate α chain, in addition to several other TCR proximal signaling
components like CD3. The invariant α chain dimerizes with the randomly recombined β
chains, forming a pre-TCR. As soon as functional β chains are produced, the pre-TCR in-
duces a signaling cascade that immediately stops further β chain recombination [30, 40, 41].
After a massive proliferation at the late DN3 stage, the developing T cells progress into the
DN4 stage (CD4-/CD8-/CD25-/CD44-), which is characterized by their reentry into the
cortex, the downregulation of the pre-TCR, the recombination of the α chain locus and the
co-induction of CD4 and CD8. In the course of these processes, the DN4 cells transit into
the DP stage (αβTCR+, CD4+/CD8+/CD25-/CD44-), as they co-express CD4 and CD8
in addition to a TCR with completely recombined α and β chains [42, 43, 44, 45, 46, 47].
As a consequence of the stochastic rearrangement of α and β chains, some DP thymo-
cytes express TCRs that are not able to recognize peptide-MHC complexes. In a process
called positive selection, those cells are efficiently eliminated from the DP thymocyte pool,
ensuring that only cells with functional TCRs continue the differentiation into mature T
cells [48, 49]. Positive selection is mainly mediated by cTECs, which present autoantigens
on MHCI class I and class II molecules to the DP thymocytes. Only upon low affin-
ity/avidity interactions between TCRs and peptide:MHC complexes, the corresponding
DP thymocytes receive survival signals by the cTECs and can progress into the next stage.
If the TCRs of DP thymocytes cannot recognize peptide:MHC complexes, they fail to re-
ceive survival signals and die by neglect. However, if the interactions between the TCRs
and the peptide:MHC complexes are too strong, the cTEC induces apoptosis in the corre-
sponding DP thymocytes, as their highly autoreactive TCR might elicit severe autoimmune
reactions in the periphery [50]. In general, only 3-5 % of all DP thymocytes are positively
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selected for further differentiation [24].
The transition into the next stage is accompanied by an important lineage decision. In
response to the cognate low-affinity interaction with MHC class I or class II molecules,
the DP thymocytes down-regulate one co-receptor (CD4 or CD8) and differentiate into
CD4SP or CD8SP thymocytes, the precursors of CD4+ T cells (TH cells) and CD8
+
T cells (CTLs)[34]. Simultaneously, the positively selected thymocytes migrate into the
medulla, where they are subjected to another selection procedure, which is mediated by
mTECs [50, 51].
In contrast to cTECs, mTECs are capable of expressing and presenting autoantigens, which
are normally restricted to specific peripheral tissues. Thus, the TCRs of the SP thymo-
cytes are tested for their reactivity against autoantigens, which are normally not present
in the thymus. The expression of tissue-restricted antigens by mTECs depends partially
on AIRE (autoimmune regulator), a transcription factor, which promotes the ectopic ex-
pression of genes such as insulin, IRBP (interphotoreceptor retinoid-binding protein) or
myelin protein zero [52, 53]. Additionally, mTECs can also transfer these ectopic antigens
to DCs for presentation [54]. After having entered the medulla, the SP thymocytes inten-
sively interact with the mTECs and the DCs [34, 50]. Only SP thymocytes that do not
recognize self-peptide:MHC complexes on the APCs are allowed to complete the differen-
tiation into conventional naive CD4+ or CD8+ T cells. If cognate interactions between
TCRs and autoantigen:MHC complexes can be established, the corresponding SP thymo-
cyte either receives a death signal and is eliminated via apoptosis or differentiates into a
regulatory T cell (Treg). Most likely, the decision between the induction of apoptosis and
the differentiation into Tregs depends on the strength of the interaction between the SP
thymocyte and the mTEC. Whereas strong interactions are thought to promote apoptosis,
intermediate interactions might support the deviation into Tregs. These thymus-derived
Tregs can enter the periphery and suppress autoimmune-reactions in an antigen-dependent
manner [54, 55]. The mTEC-mediated negative selection of SP thymocytes, which are non-
reactive to tissue-specific self-antigens, as well as the elimination and clonal deviation of
autoreactive SP thymocytes are important immunological mechanisms, which minimize the
risk of T cell-driven autoimmunity. The condition that results from these thymus-intrinsic
processes is called central tolerance [22, 49, 50].
In the course of negative selection in the medulla, the SP thymocytes develop from an
immature/semi-mature into a mature state, which can be monitored by the differen-
tial surface expression of CD62L and CD69 (immature = CD62L-/CD69+ and mature
= CD62L+/CD69intermediate). During this maturation process, the SP thymocytes ob-
tain full immunological functionality and resistance to various apoptotic stimuli (e.g.
dexamethasone). As mature SP thymocytes, the cells have completed their development
and emigrate at the CMJ through the perivascular space into the blood to become a part
of the peripheral T cell pool [24, 26, 34].
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1.3 S1P and the regulation of thymic egress
To become a part of the peripheral T cell pool that provides immunity to a broad range of
pathogens, SP thymocytes need to emigrate from the thymus into the blood after having
completed their maturation. The process of thymic egress is mainly mediated via the
sphingolipid mediator sphingosine-1-phosphate (S1P) [24, 26, 34].
1.3.1 S1P metabolism
Sphingosine-1-phosphate is a pleiotropic bioactive sphingolipid, which is in involved in the
regulation of diverse physiological processes besides lymphocyte trafficking, such as cell
growth, differentiation or the control of vascular permeability [56, 57, 58, 59]. S1P is formed
intracellularly via the phosphorylation of sphingosine, the molecular backbone of most
sphingolipids, by two specific kinases, sphingosine kinase 1 or 2 (SPHK1 or -2). Although
both kinases are ubiquitously expressed, they differ in their subcellular localization, their
spectrum of agonists and partially in their involvement in different cellular functions [60,
61]. Whereas SPHK1 is a cytosolic protein, which is activated and translocated to the
plasma membrane in response to a variety of different stimuli, such as growth factors,
hormones or cytokines, SPHK2 is localized in the nucleus, the mitochondria or other
intracellular compartments [62, 63, 64, 65, 66, 67]. Whereas SPHK1 can be activated by
EGF (epidermal growth factor), phorbolesthers or hypoxia in a context- and cell type-
dependent manner, SPHK2 agonism is insufficiently understood [68, 69, 70, 71]. However,
due to the ubiquitous expression of SPHK1 and SPHK2, S1P is present in almost every cell
type [72]. Although intracellular functions of S1P, like the regulation of histon acetylation
or the role as co-factor for TRAF2 (TNF receptor associated factor 2) in the NF-κB (nuclear
factor kappa B) pathway, have been described, a considerable amount of S1P is exported
into the extracellular space, where it acts as auto- and paracrine signaling molecule [59,
69, 73]. Even though several in vitro studies suggested that the release of S1P from the
cytosol is mediated by the family of ABC transporters (ATP binding cassette), only SPNS2
(spinster homolog 2), a member of the major facilitator superfamily of transmembrane
proteins, was found to be involved in the release of S1P from selected cell types in vivo [74,
75, 76, 77, 78].
While S1P is bound to albumin or HDL (high-density lipoprotein) in the plasma, no car-
riers are known which bind extracellular S1P in the interstitial fluids of tissues [26, 79].
Extracellular S1P signals via the interaction with five non-redundant G-protein-coupled
cell surface receptors (GPCRs), S1P receptor 1  5 (S1PR1 - 5) [80]. Whereas S1PR1-3
are broadly expressed in most tissues, the expression of S1PR4 is restricted to lymphoid
tissues and the lung, and S1PR5 to the brain, the skin and the spleen. In addition to
the differential expression, each S1P receptor is coupled to a different set of G proteins,
which induce specific down-stream signaling pathways upon engagement. Thus, S1P sig-
naling is involved in a broad spectrum of different physiological processes, which are sum-
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marized in [81]. In contrast to the production of S1P, which is catalyzed by only two
kinases, six different enzymes are able to degrade S1P [79]. In general, these enzymes can
be subdivided into the S1P lyase, which irreversibly degrades S1P into hexadecanal and
phosphoethanolamine, and 5 different phosphatases (SPP1-2 (S1P phosphatase), LPP1-3
(phospholipid phosphatase)), which dephosphorylate S1P back to sphingosine [79]. S1P
lyase is broadly expressed and localized to the ER (endoplasmic reticulum) [82, 83]. On
the one hand, the terminal degradation of S1P by S1P lyase is necessary to limit the
intracellular levels of S1P and thus the amount that is available for intracellular func-
tions or for the export into the interstitium [59, 79]. On the other hand, the conversion
of S1P into hexadecanal and phosphoethanolamine by S1P lyase represents a biochemical
one-way road between sphingolipid and glycerolipid metabolism, as hexadecanal can be
used for palmitoyl-CoA (Coenzyme A) synthesis and phosphoethanolamine for the syn-
thesis of phosphatidylethanolamine [84, 85]. The S1P dephosphorylating enzymes can be
subgrouped by their substrate specificities and their subcellular localization. Whereas
SPP1 and -2 are ER-resident proteins with considerable specificity for S1P, LPP1-3 are
cell surface proteins with broad specificity for phosphorylated lipids. As the active sites
of LPP1-3 are directed into the extracellular space, these enzymes can dephosphorylate
interstitial S1P. Consequently, SPP1-2 regulate intracellular levels of S1P, while LPP1-3
regulate extracellular levels of S1P and thus signaling via S1P receptors [86, 87, 88, 89, 90].
Additionally, the dephosphorylation by phosphatases is considered as a sphingolipid recy-
cling mechanism, as the generated sphingosine can be reused for the production of complex
sphingolipids, such as sphingomyelins [85].
1.3.2 S1P-mediated thymic emigration of mature SP thymocytes
Within the thymus, the interstitial S1P levels are inhomogeneously distributed (Figure 1.2)
[26, 79]. On the one hand, the activity of S1P degrading enzymes, such as LPP3 on
TECs and S1P lyase in DCs (and thymocytes), results in low S1P levels in the whole
parenchyma [89, 91]. On the other hand, the robust SPHK-dependent production of S1P
by neural crest-derived pericytes and presumably also vascular endothelial cells leads to
elevated S1P levels at the thymic exit sites to the blood stream (the perivascular space at
the CMJ) [78, 92]. The resulting S1P gradient between the parenchyma and the perivas-
cular space provides directional information, where cells can leave the thymus into the
circulation [79]. As long as they are immature (not sufficiently negatively selected), SP
thymocytes are insensitive to the S1P gradient [26]. This condition is maintained by CD69,
which represses the (surface) expression of S1PR1 [92]. Upon maturation (negative selec-
tion is completed), however, SP thymocytes become gradually sensitive to the S1P gradient
via up-regulation of the transcription factor KLF-2 (krueppel-like factor 2), which strongly
promotes the expression of S1PR1. In a feedback loop, initial signaling via the S1P-
S1PR1 axis causes down-regulation of CD69, which in turn supports further expression
of S1PR1 [93, 94, 95, 96]. At the end of this maturation process, the SP thymocytes are
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egress-competent, as they can process the directional information of the S1P gradient via
robust expression of S1PR. Presumably, the mature SP thymocytes are recruited along
the S1P gradient into the perivascular space, where they form contacts with the vascular
endothelium [26, 79, 92]. In response to the high S1P levels in the blood, which are even
higher than those in the perivascular space, the mature SP thymocytes subsequently trans-
migrate across the vessel wall and enter the blood stream as T cells [26, 59, 97]. Although
it is known that the high levels of S1P in the blood, which are collectively maintained
by vascular endothelial cells, hepatocytes, erythrocytes and platelets, are indispensable
for efficient thymic egress, the underlying mechanisms, by which circulatory S1P affects
the mature SP thymocytes on the abluminal side of the blood vessels, are still insuffi-
ciently understood[78, 79, 98, 99]. Likewise, the exact intrathymic architecture of the S1P
gradient, especially in the perivascular space, remains unclear [79].
Generally, S1PR1 is rapidly internalized from the cell surface upon ligation of S1P. There-
fore, almost all S1PR1s are engaged and subsequently internalized after the mature SP
thymocytes have entered the blood stream as naive T cells. In this desensitized condition,
the cells are unresponsive to further stimulation with S1P, are thus no longer attracted by
the (high levels of) S1P in the blood and can leave the vasculature somewhere else in the
organism [100, 101]. Canonically, naive T cells transmigrate via HEVs into lymph nodes,
where they form contacts with APCs to screen for cognate antigens [15].
1.3.3 Excursus: S1P-dependent lymph node egress of circulating lymphocytes
Worthy of note is that S1P gradients are not only important to mediate egress of mature
SP thymocytes into the blood, but also to facilitate emigration of circulating T and B cells
from lymph nodes into efferent lymphytics and back into the blood. Similar to the thymus,
S1P levels are relatively low in the lymph node parenchyma, but high at the exit sites close
to the cortical sinuses, resulting in a gradient that provides directional information, where
the lymph node can be left into the efferent lymphatics [26, 102, 103]. After entering the
lymph nodes from the blood as desensitized cells, T and B cells migrate into the T cell zones
or the B cell follicles on their search for antigens [104]. In response to the low S1P levels
in the parenchyma, both cell types gradually re-express S1PR1. Thus, the lymphocytes
become competent to sense the S1P-gradient, migrate to the exit sites and leave the lymph
nodes S1P-dependently into the efferent lymphatics [17, 26]. However, if T and B cells
are activated by cognate antigens, they need to stay in the lymph node to proliferate and
differentiate into effector cells. In this case, both cell types immediately upregulate CD69,
which suppresses S1PR1 surface expression and thus their sensitivity for the S1P gradient.
After complete differentiation, effector cells down-regulate CD69, re-express S1PR1 and
exit via the S1P gradient into the circulation [17, 105].
The increasing knowledge about S1P-mediated lymphocyte egress is of medical benefit, as
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Figure 1.2: Thymic egress of mature SP thymocytes along the S1P gradient. The layout of this figure is
based on the graphics of [59, 79].
it led to the development of novel therapeutic strategies for the treatment of people with au-
toimmune disorders. The most prominent example is the development of the drug FTY720,
which is used to treat patients with relapsing-remitting multiple sclerosis (RRMS), a severe
autoimmune disease of the central nervous system, driven by autoreactive T cells [106, 107].
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FTY720 is a synthetic analogue to sphingosine, which is phosphorylated by sphingosine
kinase 2. As phospho-FTY720, it binds to S1PR1, S1PR3, S1PR4 and S1PR5 and in-
duces their internalization from the cell surface [107, 108, 109]. Thus, although FTY720
acts agonistically, long-term treatment establishes a functional antagonism as cells down-
modulate their S1P receptors and become desensitized. Thereby, lymphocytes become un-
responsive to S1P gradients and subsequently sequestered in secondary lymphoid organs.
Consequently, FTY720 treatment extenuates neuro-inflammation, as many autoreactive
lymphocytes are hindered to reach the central nervous system [107, 110, 111].
1.4 Ceramide synthases and their role in sphingolipid metabolism
By regulating emigration of lymphocytes from thymus and lymph nodes, S1P is of fun-
damental importance for the adaptive immune system [99]. From a biochemical point
of view, S1P belongs to the class of sphingolipids, a large and diverse group (close to
600 different species [112]) of bioactive lipids, which all share a sphingoid base backbone
(e.g. sphingosine or dihydrosphingosine) as common feature (Figure 1.3). Due to their
hydrophobic character, most sphingolipids are integral constituents of membranes. Sphin-
golipids have crucial physiological and pathophysiological functions, as they are involved
in various cellular processes, such as growth, survival, inflammation or the development
of cancer [85, 113, 114]. Although the underlying mechanisms are often not exactly un-
derstood, it is generally accepted that sphingolipids function either directly by acting as
signaling molecules, or indirectly by influencing the biophysical properties of membranes,
which can affect e.g. transport, localization and function of transmembrane proteins [84].
The biochemical network of sphingolipid metabolism consists of various interconnected
and mostly bidirectional pathways that are regulated by a large number of different en-
zymes. However, the only way to enter sphingolipid metabolism is the de novo synthesis
pathway, in which sphingoid bases are synthesized from non-sphingoid substrates by SPT
(serine palmitoyltransferase). Likewise, sphingolipids can exclusively be converted into
non-sphingolipid molecules by S1P lyase, which catalyzes the breakdown of S1P into hex-
adecanal and phosphoethanolamine. Thus, despite its complexity, sphingolipid metabolism
is an almost self-contained system [85, 114].
HO
NH2
OH
Sphingosine
HO
NH2
OH
Dihydrosphingosine
Figure 1.3: Chemical structures of sphingosine and dihydrosphingosine (sphinganine). Red circles indi-
cate the position, where the two molecules differ from each other. This figure was taken from [115] and
modified.
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1.4.1 Sphingolipid metabolism
The generation of new sphingolipids via the de novo synthesis pathway starts at the ER
with the condensation of serine and palmitate to 3-ketodihydrosphingosine (Figure 1.4).
This rate-limiting step is catalyzed by the serine palmitoyltransferase (SPT), whose activ-
ity is regulated by ORMDL proteins (Orm-like) [116, 117]. Next, 3-ketodihydrosphingsine
is reduced by 3-ketosphinganine reductase (3-KR) to dihydrosphingosine, which is subse-
quently converted into dihydroceramide via N-acylation with fatty acids by enzymes of the
ceramide synthase family (CERS1-6) [118]. This step marks the beginning of sphingolipid
diversification, as fatty acids of different chain lengths (mostly C14  C26) can be used for
dihydroceramide synthesis [85, 119]. Nonetheless, all dihydroceramides are enzymatically
transformed into ceramides by desaturase (DES) [120].
Ceramides are the central molecules within sphingolipid metabolism, as they serve as
substrates for all major anabolic pathways [113]. Additionally, several studies indicate
that ceramide species themselves are important bioactive molecules, which are involved in
the induction of apoptosis, the inhibition of cell growth and the control of autophagy [121,
122, 123, 124, 125]. In general, it is assumed that ceramides mediate these processes
via the formation of special lipid microdomains in mitochondrial membranes or in the
plasma membrane that putatively control membrane-proximal signaling events [114, 115].
Furthermore, ceramides can directly and indirectly regulate the activity of proteins such
as PP2A (protein phosphatase 2A), PKCζ (protein kinase Cζ) or p38 and thus influence
cellular survival [126, 127, 128].
By vesicular trafficking or by CERT (ceramide transporter), a special ceramide trans-
porter, ceramides are transferred from the ER to the Golgi apparatus [130, 131]. In
the golgi network, ceramides can be converted into various subclasses of complex sph-
ingolipids, such as sphingomyelins (SMs), via the addition of phosphocholine head groups
by SMS enzymes (sphingomyelin synthase), or glycosphingolipids (GSLs), like cerebro-
sides or gangliosides, via the addition of mono- or oligosaccharides by several different en-
zymes (glycosphingolipid synthases (GCS)), such as CGT (ceramide glucosyl transferase),
LCS (lactosyl ceramide synthase) or GlcNAcT (N-acetylgalactosamine transferase) [85, 132,
133]. Eventually, most of these complex sphingolipids are shuttled to the plasma mem-
brane, where they influence the biophysical properties of the lipid bilayer, organize lipid
microdomains and contribute to intercellular recognition processes [84, 134].
The breakdown of complex sphingolipids occurs either at the plasma membrane or via the
endocytic pathway and is mediated by a large number of different enzymes. In general, sph-
ingomyelins are degraded by sphingomyelinases (SMases), a group of five different enzymes,
via the conversion into ceramide and phosphocholine. Although all sphingomyelinases cat-
alyze the same biochemical reaction, they differ in their expression pattern, their subcellular
localization and their evolutionary origin. Whereas the alkaline sphingomyelinase is ex-
clusively expressed in intestine and liver, processing sphingomyelins from food, the other
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[129]
four sphingomyelinases, acid sphingomyelinase (aSMase) and neutral sphingomyelinase 1-3
(nSMase), are ubiquitously expressed [85, 135, 136]. Although, aSMase is predominantly
localized to lysosomes, degrading sphingomyelins that were internalized by endocytosis, it
can also be secreted into the extracellular space (sSMase), where it might degrade sph-
ingomyelins in the plasma membrane or blood plasma [137, 138]. nSMases are associated
with the plasma membrane, the Golgi apparatus or the ER, degrading sphingomyelins on
the cytosolic leaflet of the lipid bilayer. Worthy of note is that recent studies indicated
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that nSMase1 functions rather as lysophospholipase for lyso-PAF (platelet-activating fac-
tor) than as SMase for sphingomyelins [139, 140, 141]. In contrast, the breakdown of
glycosphingolipids occurs excusively via the endolysosomal pathway by a plethora of hy-
drolytic enzymes that successively remove the carbohydrate moieties from the ceramide
backbone (GCases (glycosidases)) [85, 133]. Ceramides that are produced by the break-
down of sphingomyelins and glycosphingolipids can be further degraded by ceramidases
(CDases), a group of five different enzymes, acid ceramidase (aCDase or AC), neutral
ceramidase (nCDase or NC) and alkaline ceramidase1-3 (alkCDase or ACER1-3). Al-
though all ceramidases degrade ceramides via conversion into sphingosine by deacylation,
their subcellular localization and biochemical properties differ from each other [142]. The
acid ceramidase is a lysosomal protein, which degrades ceramides that originate from the
breakdown of endocytosed sphingomyelins and glycosphingolipids [142, 143]. The neutral
ceramidase is a type II transmembrane protein, which can be cleaved at the N-terminus
to produce a soluble form, which associates with the extracellular leaflet of the plasma
membrane. Thus, NC is involved in the degradation of ceramides at the cell surface and in
the interstitium [142, 144, 145]. The alkaline ceramidases share a high degree of homology
and localize mainly to the ER and the Golgi apparatus, where they presumably degrade
ceramides from various origins [85, 142].
The degradation of ceramides by ceramidases is the only way to produce sphingosine, which
is sufficiently amphipatic to freely diffuse from one membrane to another [85]. Sphingo-
sine is either reacylated to ceramides by ceramide synthases or phosphorylated to S1P by
sphingosine kinases (SPHKs). The processes of recycling back into ceramides and thus
into sphingolipid anabolism is termed salvage pathway and accounts for more than 50%
of the produced sphingosine [114, 115]. Despite its pleiotropic physiological functions, S1P
is likewise the final product of sphingolipid catabolism. Via the activity of S1P lyase,
S1P is irreversibly converted into the non-sphingoid molecules hexadecanal and phospho-
ethanolamine. As this process is the only way to break down sphingoid bases, it represents
the exit from sphingolipid metabolism. Nonetheless, S1P can also be dephosphorylated to
sphingosine by different phosphatases (SPPs). Thus, even S1P can be redirected into the
salvage pathway [85].
1.4.2 Ceramide synthases as central enzymes in sphingolipid metabolism
Ceramides represent the most central sphingolipid species, as they are the substrate for the
synthesis of all complex sphingolipids [113]. Therefore, ceramide synthases, which catalyze
the formation of (dihydro-)ceramides by N-acylation of (dihydro-)sphingosine with fatty
acids, are regarded as the central enzymes in the network of sphingolipid metabolism [129].
The family of ceramide synthases comprises six members in mammals (CERS1-6). All
CERSs are transmembrane proteins with 5  8 transmembrane domains (depending on the
algorithm for prediction) [146]. Although some studies demonstrate that ceramide syn-
thases can be present in mitochondria and the Golgi apparatus, they mainly localize to the
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ER and the nuclear membranes [147, 148, 149, 150]. Besides a TLC (TRAM/LAG1/CLN8)
domain, which harbors the enzymatic activity within the Lag1p motif, all ceramide syn-
thases, except for CERS1, contain a Hox-like domain of controversially discussed func-
tion [151, 152, 153, 154]. Although all members of the CERS family catalyze the same
biochemical reaction, each CERS is restricted to an individual spectrum of fatty acid
chain lenghts that can be used for N-acylation. Whereas, CERS2 and CERS3 mainly use
fatty acid chain lengths of C20 to C26, CERS5 and CERS6 are restricted to C14 and C16
fatty acids, while CERS1 and CERS4 cover the intermediate spectrum. Thus, ceramide
synthases are functionally non-redundant, as each enzyme is responsible for the production
of (dihydro-)ceramides and the subsequent complex sphingolipids with specific acyl chain
lengths [129, 146]. In addition to diverging substrate specificities, ceramide synthases are
differentially expressed in various tissues [155].
1.4.2.1 CERS1 CERS1 has substrate specificity for C18 fatty acids and is almost
exclusively expressed in brain and skeletal muscle [147, 149, 155, 156, 157]. In vitro ex-
periments and analyses of CERS1-deficient mice demonstrated that CERS1 and/or C18
sphingolipids are crucially involved in the regulation of cerebellar development and neu-
ronal turnover, as well as in the suppression of head and neck cancer [158, 159]. Addi-
tional studies indicated that CERS1 and/or C18 sphingolipids increase the sensitivity to
chemotherapeutic drugs, such as cisplatin, carboplatin, vinctistin and doxorubicin. How-
ever, the underlying mechanisms of action are insufficiently understood [150].
1.4.2.2 CERS2 CERS2 has substrate specificity for C22 and C24 fatty acids and is
not only almost ubiquitously expressed, but also by far the most abundant CERS family
member, with highest expression levels in liver and kidney [155]. Due to these characteris-
tics, CERS2 has been intensively studied in various in vitro and in vivo studies. Especially
analyses of CERS2-deficient mice revealed that CERS2 is involved in various important
physiological processes, such as brain myelination, cellular homeostasis in the liver, insulin
sensitivity and neutrophil migration [160, 161, 162, 163]. As CERS2-deficient mice lack
C22 and C24, but accumulate C16 sphingolipids and sphingoid bases, which are both sup-
posed to have a cytotoxic potential [164, 165], it is generally assumed that CERS2 regulates
these processes by maintaining a balance between sphingolipids with different acyl chain
lengths [160, 162, 166, 167, 168, 169, 170, 171, 172].
1.4.2.3 CERS3 CERS3 is exclusively expressed in testes and in the skin. In con-
trast to the other CERS family members, CERS3 has a broad substrate specificity, using
not only long chain fatty acids (LCFA, C16-C20) and very long chain fatty acids (VL-
CFA, C22-C26), but also ultra-long chain fatty acids (ULCFA, >C26) for the production
of ceramides [156]. Studies with CERS3-deficient mice demonstrated that the CERS3-
dependent sphingolipids, especially those with ULCFAs, are important for cytokinesis
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during male meiosis and for the maintenance of the skin barrier [173, 174, 175].
1.4.2.4 CERS4 CERS4 has substrate specificity for C18 and C20 fatty acids and
is broadly expressed in several tissues, with highest expression levels in skin, heart and
liver [155]. Via analyses of CERS4-deficient mice, it was shown that CERS4 and CERS4-
dependent sphingolipids are crucially involved in maintaining skin functions, as they control
stem cell homeostasis, hair follicle cycling and sebum composition [176, 177].
1.4.2.5 CERS5 CERS5 has substrate specificity for C16 fatty acids and is mainly
expressed in white adipose tissue, testes, lung, spleen and thymus [178]. Due to its capac-
ity to generate C16 sphingolipids, which are suspected pro-apoptotic mediators, CERS5
has been extensively studied in vitro, revealing its putative involvement in stress-induced
p38 signaling and cell death, as well as in the sensitivity regulation to chemotherapeutic
agents, such as doxorubicin and vincristine [150, 179, 180]. Additionally, recent analyses of
CERS5-deficient mice demonstrated that CERS5 promotes diet-induced obesity and the
concomitant complications, like insulin resistance [178].
1.4.2.6 CERS6 Like CERS5, CERS6 has substrate specificity for C16 fatty acids.
Additionally, CERS6 is able to use C14 fatty acids for ceramide generation [156]. CERS6
is widely expressed with highest expression levels in the kidney and the intestine [155, 181].
The physiological role of CERS6 has been extensively analyzed by the use of CERS6-
deficient mice. The corresponding studies demonstrated that CERS6 regulates behavior
and promotes diet-induced obesity, but suppresses the development of EAE (experimental
autoimmune encephalomyelitis) [167, 182]. Moreover, recent investigations indicate a pro-
metastatic role of CERS6 in lung cancer cells [183].
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2 Aim of the study
In order to finish their developmental program and become a part of the peripheral T cell
pool, SP thymocytes undergo a maturation process after having completed negative selec-
tion. This maturation enables them to emigrate from the thymus into the circulation along
a gradient of the chemoattractive lipid mediator sphingosine-1-phosphate (S1P) [24, 26, 34].
As this egress is needed to constantly replace defective or senescent T cells and supply the
periphery with TCRs of new specificities, the thymic S1P gradient is of fundamental im-
portance for the adaptive immune system to provide effective protection against a broad
range of pathogens [19, 26, 184]. Although a considerable number of different compo-
nents (enzymes, cell types, the blood) were identified to be involved in the regulation of
S1P-dependent thymic egress, the exact architecture of the thymic S1P gradient, as well
as the underlying mechanisms that maintain functional differences in the concentration
of S1P remain poorly understood. A deeper insight into the processes that generate the
S1P gradient would be of medical interest, as S1P-mediated lymphocyte egress represents a
promising therapeutic target for the treatment of autoimmune diseases and other disorders
of the adaptive immune system [79].
It is known that the production of S1P, which can be regulated via the amount of sphingo-
sine (substrate for S1P synthesis) or via the activity of the SPHKs (mediate S1P synthe-
sis by phosphorylation of sphingosine), is of fundamental importance for S1P-dependent
thymic egress [92, 97, 103, 185, 186, 187]. Prominent regulators of free sphingosine are ce-
ramide synthases (CERS). These enzymes efficiently limit the amount of free sphingosine
by using it as substrate for the production of ceramides within the sphingolipid salvage
pathway [129, 146]. Different studies demonstrated that especially the enzymatic activity
of CERS2, the most abundant member of the ceramide synthase family, is crucial to keep
the levels of free sphingosine within physiological boundaries, e.g. in the liver [166, 188].
Moreover, recent investigations indicate that the CERS2-dependent regulation of sphingo-
sine levels might indeed affect the production of S1P in aged gastric smooth muscle cells
or the brain [189, 190].
With regard to these findings, the aim of the present study was to investigate the role
of CERS2 for the maintenance of the chemoattractive S1P gradient in the thymus and
for efficient emigration of newly formed T cells into the periphery (Figure 2.1). For this
purpose, S1P-dependent thymic egress was analyzed in wild type and CERS2-deficient
mice. Furthermore, via transfer experiments between wild type and CERS2-deficient mice
(bone marrow chimeras and thymus transplantation), the relative contribution of CERS2
in hematopoietic and thymic stromal cells to the regulation of S1P-mediated thymic egress
was determined. Additionally, analyses of CERS4-deficient mice gave insight into the
question if S1P gradients are exclusively regulated by CERS2 or also by other ceramide
synthases.
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Figure 2.1: Aim of the study. The layout of this figure is based on the graphics of [59, 79].
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3 Materials and methods
3.1 Materials
3.1.1 Devices
Device Model, company (office)
Autoclave 135T, H + P Medizintechnik (Oberschleißheim,
Germany)
Balance JB2002-G/FACT and AG285, Mettler
Toledo (Greifensee, Switzerland)
Binocular Wild Heerbrugg (Bad Dürkheim, Germany)
Blotting equipment Mini Trans-Blot Cell, Bio-Rad (Munich, Germany)
Centrifuges 5810R, 5424 and 5415R, Eppendorf (Hamburg,
Germany)
Avanti J-20XP, Beckman Coulter (Munich,
Germany)
Multifuge 4KR, Heraeus Instruments
GmbH (München, Germany)
CO2 incubator CB, Binder (Tuttlingen, Germany)
Developing machine SRX-101A, Konica Minolta (Langenhagen,
Germany)
Dissecting set FST Dumont Biology (Heidelberg, Germany)
Electropheresis chamber (agarose gels) Polymehr (Paderborn, Germany)
Electropheresis chamber (SDS-PAGE) Mini Trans-Blot Cell, Bio-Rad (Munich, Germany)
Flow cytometer Canto II and LSR, BD Bioscience (Heidelberg,
Germany)
Gel documentation Gel Max, Intas (Göttingen, Germany)
Heat block Thermomixer compact, Eppendorf (Hamburg,
Germany)
Laminar flow hood BioFlow, BDK (Sonnenbühl-Genkingen, Germany)
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Magnetic stirrer Combimac RCT, IKA (Staufen, Germany)
Microplate reader Infinite M200, Tecan (Männedorf, Switzerland)
Synergy HT, Biotek (Bad Friedrichshall, Germany)
Microscope Axiovert 100, Zeiss (Jena, Germany)
Neubauer chamber Marienfeld (Lauda-Königshofen, Germany)
PCR cycler MyCycler, Bio-Rad (Munich, Germany)
Vapoprotect, Eppendorf (Hamburg, Germany)
PH meter MP220, Mettler Toledo (Greifensee, Switzerland)
Pipettes Gilson (Middleton, USA)
ErgoLine, StarLab (Helsinki, Finland)
Pipette controller Pipetus-Akku, Hirschmann Laborgeräte (Eberstadt,
Germany)
Accu-jet pro, Brand (Wertheim, Germany)
Power supply EV-243, Consort (Turnhout, Belgium)
Elite300Plus, Schütt Labortechnik (Göttingen,
Germany)
Tissue homogenizer Precellys, Bertin (Rockville, USA)
Real-time PCR cycler iCycler iQ5 and CFX96, Bio-Rad (Munich,
Germany)
Rocker WS-10, Edmund Bühler (Hechingen, Germany)
Roller mixer RS-TR05, Phoenix Instrument (Garbsen, Germany)
Scanner Scan Maker 8700, Mikrotek (Hsinchu,Taiwan)
Spectrophotometer NanoDrop2000, Thermo Scientific (Waltham, USA)
Suction pump AC, HLC BioTech (Bovenden, Germany)
Ultrasonic homogenizer Sonoplus, Bandelin Electronic (Berlin, Germany)
Vortex mixer UNIMAG ZX3, VELP scientica (Milan, Italy)
Waterbath WNE, Memmert (Schwabach, Germany)
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3.1.2 Consumables
Consumable Model, company (office)
Capillary tips Roth (Karlsruhe, Germany)
Cell culture plates and multiwell plates Greiner Bio-one (Frickenhausen, Germany)
Cover slips Marienfeld GmbH (Lauda-Königshofen, Germany)
Falcon tubes Greiner Bio-one (Frickenhausen, Germany)
Filter paper Whatman No.4, Schleicher and Schuell (Dassel,
Germany)
Filter tips 10, 200 and 1000µl, Sarstedt (Nümbrecht, Germany)
Flow cytometry tubes Sarstedt (Nümbrecht, Germany)
Glass beads (acid-washed) Sigma-Aldrich (St. Louis, USA)
Hollow needles Braun (Melsungen, Germany)
2ml micro tubes Sarstedt (Nümbrecht, Germany)
Blood collection tubes Microvette® CB 300µl, Lithium-Heparin,
Sarstedt (Nümbrecht, Germany)
Nitrocellulose membrane Protran, Schleicher and Schuell (Dassel, Germany)
Nylon cell strainer 40 and 70 µm pore size, BD Biosciences,
(Heidelberg, Germany)
Pasteur pipettes Roth (Karlsruhe, Germany)
Pipette tips Roth (Karlsruhe, Germany)
Polypropylene reaction tubes Starlab (Helsinki, Finland)
Radiographic film Hyperfilm MP, Amersham
Biosciences (Buckinghamshire, UK)
Sterile filters 0.2 and 0.45 µm, Schleicher and Schuell (Dassel,
Germany)
Syringes Braun (Melsungen, Germany)
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PCR reaction tubes 200µl thin wall tubes, Axygen (Tewksbury, USA)
Serological pipettes 5, 10, 25ml, Greiner Bio-one (Frickenhausen,
Germany)
RT-PCR plates Bio-Rad (Munich, Germany)
RT-PCR seals Bio-Rad (Munich, Germany)
3.1.3 (Bio-)chemicals
Reagent Company (office)
2-Mercaptoethanol Roth (Karlsruhe, Germany)
2-Propanol Merck (Darmstadt, Germany)
Acrylamide/Bisacrylamide solution (30%) Roth (Karlsruhe, Germany)
Agarose Life Technologies (Carlsbad, USA)
Ammonium chloride (NH4Cl) Sigma-Aldrich (St. Louis, USA)
Ammonium persulfate (APS) Roth (Karlsruhe, Germany)
Antipain Sigma-Aldrich (St. Louis, USA)
Aprotinin Sigma-Aldrich (St. Louis, USA)
Benzamidin Roth (Karlsruhe, Germany)
Bovine serum albumin (BSA) Roth (Karlsruhe, Germany)
Bromphenolblue Roth (Karlsruhe, Germany)
Chloroform Roth (Karlsruhe, Germany)
Dimethyl sulfoxide (DMSO) Roth (Karlsruhe, Germany)
Dithiothreitol (DTT) Applichem (Gatersleben, Germany)
DNA loading dye (6x) Thermo Scientific (Waltham, USA)
dNTPs Thermo Scientific (Waltham, USA)
Ethanol VWR(Darmstadt, Germany)
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Ethidiumbromide (EtBr) Roth (Karlsruhe, Germany)
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich (St. Louis, USA)
Fixable viability dye eFluor450 eBioscience (San Diego, USA)
Glycerol Grüssing (Filsum, Germany)
Glyerolphosphate Sigma-Aldrich (St. Louis, USA)
Glycin Roth (Karlsruhe, Germany)
Hydrochloric acid (HCl) Roth (Karlsruhe, Germany)
Leupeptin Sigma-Aldrich (St. Louis, USA)
Methanol Roth (Karlsruhe, Germany)
Milk powder Roth (Karlsruhe, Germany)
Phenylmethane sulfonyl fluoride (PMSF) Sigma-Aldrich (St. Louis, USA)
Ponceau S Roth (Karlsruhe, Germany)
Potassium bicarbonate (KHCO3) Sigma-Aldrich (St. Louis, USA)
Sodium azide (NaN3) Roth (Karlsruhe, Germany)
Sodium chloride (NaCl) Roth (Karlsruhe, Germany)
Sodium deoxycholate Sigma-Aldrich (St. Louis, USA)
Sodium dodecyl sulfate (SDS) Roth (Karlsruhe, Germany)
Sodium fluoride (NaF) Roth (Karlsruhe, Germany)
Sodium orthovanadate Sigma-Aldrich (St. Louis, USA)
Sodium pyrophosphate Sigma-Aldrich (St. Louis, USA)
Tetramethylethylenediamine (TEMED) Sigma-Aldrich (St. Louis, USA)
Tris(hydroxymethyl)aminomethane (TRIS) Roth (Karlsruhe, Germany)
Triton X-100 Roth (Karlsruhe, Germany)
TRIzol Reagent Thermo Scientific (Waltham, USA)
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Trypanblue solution Sigma-Aldrich (St. Louis, USA)
3.1.4 Kits and enzymes
Product Company (office)
Annexin V Apoptosis Detection Kit APC eBioscience (San Diego, USA)
Anti-Biotin Microbeads Miltenyi (Bergisch Gladbach, Germany)
Anti-CD45 Microbeads Miltenyi (Bergisch Gladbach, Germany)
BCA Protein Assay Reagent Thermo Scientific (Waltham, USA)
DNase I (RNase-free) Thermo Scientific (Waltham, USA)
Dreamtaq DNA Polymerase Thermo Scientific (Waltham, USA)
ECL PlusWestern-Blotting Substrate Thermo Scientific (Waltham, USA)
Foxp3/Transcription Factor Staining Buffer
Set
eBioscience (San Diego, USA)
High-Capacity cDNA Reverse Transcription
Kit
Thermo Scientific (Waltham, USA)
iTaq Universal SYBR Green Supermix Bio-Rad (Munich, Germany)
Kapa Sybr Fast qPCR Mastermix for
Bio-Rad iCycler
Peqlab (Erlangen, Germany)
Liberase TM Roche (Mannheim, Germany)
Proteinase K Peqlab (Erlangen, Germany)
3.1.5 DNA and protein standards
Product Company (office)
GeneRuler 100 bp DNA ladder Thermo Scientific (Waltham, USA)
Protein-Marker IV ('Prestained') Peqlab (Erlangen, Germany)
Precision Plus Protein All Blue Prestained
Protein Standards
Bio-Rad (Munich, Germany)
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3.1.6 Buffer and sera
Product Company (office)
Phosphate-buffered saline (PBS) Sigma-Aldrich (St. Louis, USA)
Lymphoprep Stem cell technologies (Vancouver, Canada)
Fetal calf serum (FCS) Sigma-Aldrich (St. Louis, USA)
3.1.7 Antibodies
Target Clone Conjugate Host Use Dilution Company (office)
CD4 GK1.5 or
RM4
Fluorochrome Rat FC According to
manufac-
turer's
instructions
Biolegend /San
Diego, USA)
CD8a 53-6.7 Fluorochrome Rat FC According to
manufac-
turer's
instructions
Biolegend /San
Diego, USA) or BD
Biosciences,
(Heidelberg,
Germany)
CD11c N418 Fluorochrome Armenian
hamster
FC According to
manufac-
turer's
instructions
Biolegend /San
Diego, USA)
CD25 7D4 or
PC61
Fluorochrome Rat FC According to
manufac-
turer's
instructions
BD Biosciences,
(Heidelberg,
Germany)
CD31 390 Fluorochrome Rat FC According to
manufac-
turer's
instructions
Biolegend /San
Diego, USA)
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CD44 IM7 Fluorochrome Rat FC According to
manufac-
turer's
instructions
Biolegend /San
Diego, USA) or BD
Biosciences,
(Heidelberg,
Germany)
CD45 30-F11 Fluorochrome Rat FC According to
manufac-
turer's
instructions
Biolegend /San
Diego, USA)
CD45.1 A20 Fluorochrome Mouse FC According to
manufac-
turer's
instructions
Biolegend /San
Diego, USA)
CD45.2 104 Fluoruchrome
or Biotin
Mouse FC According to
manufac-
turer's
instructions
Biolegend /San
Diego, USA)
CD62L MEL14 Fluorochrome Rat FC According to
manufac-
turer's
instructions
Biolegend /San
Diego, USA)
CD69 H1.2F3 Fluorochrome Armenian
hamster
FC According to
manufac-
turer's
instructions
Biolegend /San
Diego, USA)
EpCam G8.8 Fluorochrome Rat FC According to
manufac-
turer's
instructions
Biolegend /San
Diego, USA)
F4/80 BM8 Fluorochrome Rat FC According to
manufac-
turer's
instructions
Biolegend /San
Diego, USA)
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Fc-
Block
. - FC According to
manufac-
turer's
instructions
Biolegend /San
Diego, USA)
Ki67 SolA15 Fluorochrome Rat FC According to
manufac-
turer's
instructions
eBioscience (San
Diego, USA)
CERS2 - - Rabbit FC
WB
1:200
1:1000
[191]
Actin Polyclonal - Rabbit WB 1:2000 Sigma-Aldrich (St.
Louis, USA)
Phospho-
p38
Polyclonal - Rabbit WB 1:1000 Cell
Signaling (Danvers,
USA)
p38 Polyclonal - Rabbit WB 1:1000 Cell
Signaling (Danvers,
USA)
Tubulin YL1/2 - Rat WB 1:2000 Merck Milli-
pore (Darmstadt,
Germany)
Rabbit
IgG
Polyclonal Fluorochrome Donkey FC 1:800 Jackson Immunore-
search (West Grove,
USA)
Rabbit
IgG
Polyclonal HRP Goat WB 1:5000 Santa Cruz (Dallas,
USA)
Rat
IgG
Polyclonal HRP Goat WB 1:5000 Santa Cruz (Dallas,
USA)
3.1.8 Primer for genotyping
Target locus Primer name Sequence (5'- ... -3')
Cers2 2_geno_for GTC AGT CTG CAT GCA GTT ACC TCT CC
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Cers2 2_geno_rev GAG ACA AGC ACA TCC CCA AAG CAC
Cers2 2_βneo GGG ATC CAC TAG TTC TAG CCT CGA
3.1.9 Primer for RT-PCR
Target Internal number Sequence (5'- ... -3')
Gapdh 3 TCA CCA CCA TGG AGA AGG C
4 GCT AAG CAG TTG GTG GTG CA
Cers1 73 GCC CTC TGT CTT CTA TGA CTG G
74 GGC ATA GAT GGA GTG GCA GTA G
Cers2 11 GGC GCT AGA AGT GGG AAA C
12 TCG AAT GAC GAG AAA GAG CAG G
Cers3 88 CAC TAT CTC GAG CCC TTC TTC
89 CCT CTT CGT TGT CAC TCC TC
Cers4 67 CTG CGC ATG CTC TAC AGT TTC
68 CCC TCG AGC CAT CCC ATT C
Cers5 77 TGA GAC AAC CCA CAA AAA CAA CC
76 TGG CTT TAC AAG TCC CCT GC
Cers6 92 AGG GTT GAA CTG CTT CTG G
93 GTT CCG TTG GTG GTT GTT G
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3.1.10 Mice
Common
strain name
Official strain name Background Description References
Cers2gt B6;129S4-
Cers2Gt(S16-4B1)Sor/Cnrm
C57BL/6J
(Purity ≥
98,4375%)
Derived from an ES cell
clone in which the genomic
locus of CERS2 was
mutated by the insertion of
the gene trap (gt) vector
ROSAFARY. Cers2+/+ =
wild type; Cers2+/gt =
heterozygous mutation;
Cers2gt/gt = homozygous
mutation =
CERS2-deficient.
[160, 166,
161]
Cers4Δneo Cers4tm1.1Kwi/Cnrm C57BL/6N
(Purity ?)
Derived from an ES cell
clone in which the genomic
locus of CERS4 was
mutated. Cers4+/+ =
wild type; Cers4+/Δneo =
heterozygous mutation;
Cers4Δneo/Δneo =
homozygous mutation =
CERS4-deficient.
[176]
CD45.1+ B6.SJL-
PtprcaPepcb/BoyJ
C57BL/6J
(congenic)
This strain carries the
differential pan leukocyte
marker Ptprca, commonly
known as CD45.1 or Ly5.1.
[192, 193,
194, 195, 196,
197, 198, 199]
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3.2 Methods
3.2.1 Animal experimental methods
3.2.1.1 Mouse breeding and husbandry The Cers2gt and Cers4Δneo mouse strains
were bred in IVCs (individually ventilated cages) under SPF-conditions (specific-pathogen
free) in the animal facility of the LIMES Institute of the University of Bonn (LIMES
GRC (genomic resource center)). The CD45.1+ mouse strain was bred under the same
conditions in the Haus für experimentelle Therapie (HET) of the University hospital of
Bonn. All breedings and experimental procedures were approved by the LANUV NRW
(Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen; approval
numbers: 84-02.04.2011.A402 and 84-02.04.2015.A496) and conducted according to the
respective institutional guidelines. In general, Cers2+/gt females were bred with Cers2+/gt
males to produce Cers2+/+ and Cers2gt/gt mice for experiments and analyses. The same
breeding scheme was applied for the Cers4Δneo strain. Wild type and CERS-deficient mice
of both genders (as indicated in the figure legends) were used for analyses at an age of 8 
14 weeks. The heterozygous offspring was used for further breeding.
3.2.1.2 Isolation of genomic DNA and genotyping of Cers2gt/gt mice The geno-
type of mice from the Cers2gt strain was determined by PCR on genomic DNA from tail
tips. To isolate genomic DNA, 200µl lysis buffer plus 1µl Proteinase K (Stock: 20mg/ml)
was added to each tail tip and samples were incubated for 3 - 4 h at 37°C under mild
agitation. After the tail tip has been dissolved, samples were centrifuged for 10min at
10000 x g and RT. The supernatant was decanted into a new 1.5ml reaction tube, 500 µl
2-propanol were added to each sample and the tubes were inverted several times. Then,
samples were centrifuged for 30min at 12000 x g and 4°C. The supernatant was discarded
and the pellet was rinsed once with 1ml 70% ethanol. After another centrifugation for
10min at 10000 x g and 4° C, the supernatant was discarded and the pellet was air dried.
Finally, the DNA was dissolved in 200  500µl TE pH 8.0.
Lysis buffer Component Final concentration
Tris-HCl 100 mM pH 8.0
EDTA 5 mM
SDS 0.5 %
NaCl 200 mM
A. bidest
For genotyping of mice from the Cers2gt strain, a 3 primer strategy was applied, which
generates an amplicon of 400 bp for the wild type allel and an amplicon of 564 bp for
the Cers2gt allel (primer sequences can be found in 3.1.8). The following components and
thermal cycler conditions were used:
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Reaction setup Component (concentration) Volume for 1x reaction [µl]
A. bidest 12
DMSO 0.8
10x DreamTaq Buffer 2
dNTP's (10 mM) 1
2_geno_for (10 pmol/µl) 1
2_ßneo (10 pmol/µl) 1
2_geno_rev (10 pmol/µl) 1
DreamTaq 0.2
DNA 1
Σ 20
Thermal cycler program Step Temperature [°C] Time [mm:ss] Cycles
1 94 05:00 1x
2 94 00:30
2 61 00:30 35x
2 72 00:40
3 72 10:00 1x
4 4 ∞ -
After the genotyping PCR was completed, amplicons were separated via agarose gel elec-
trophoresis (2%) to determine the genotype of the corresponding animals (see 3.2.2.1).
3.2.1.3 Blood collection by cardiac puncture To collect blood, mice were anes-
thetized with isoflurane, laid on their back and cleaned with 70% ethanol. Without opening
the abdomen or the thoracic cavity, the heart was directly punctured with a 27G needle
on a 1ml syringe and up to 1ml blood was carefully withdrawn. Afterwards, the mice
were sacrificed by cervical dislocation. To prevent coagulation, blood was either trans-
ferred into heparinized blood collection tubes (for isolation of plasma) or gently mixed
with 0.5M EDTA (up to 500µl blood per 50 µl EDTA) in standard 1.5ml reaction tubes
(for isolation of PBMCs).
For the isolation of plasma, the anticoagulated blood was centrifuged in the heparinized
tubes for 5min at 2000 x g and 4°C. Then, the plasma phase was harvested, transferred
into a new 1.5ml reaction tube and snap-frozen in liquid N2.
For the isolation of PBMCs, the anticoagulated blood was diluted with PBS containing
2% FCS and 2mM EDTA to a final volume of 1.2ml and stored at RT until further
processing (3.2.4.1).
3.2.1.4 Dissection of thymi, spleens, lymph nodes and bones To dissect lym-
phoid organs and bones, mice were sacrificed by cervical dislocation, laid on their back and
cleaned with 70% ethanol. First, the abdomen and the thoracic cavity were opened with
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sterile dissection instruments to remove the thymus, the spleen and the inguinal lymph
nodes. All organs were transferred into PBS containing 1.5ml reaction tubes and stored
on ice until further processing (3.2.4.2). Next, tibia and femur of each leg were dissected,
carefully cleaned from connective and muscle tissue, transferred into 1.5ml tubes contain-
ing PBS and stored on ice until further processing (3.2.4.5).
3.2.1.5 Transcardial perfusion In order to measure the precise tissue levels of dif-
ferent sphingolipids from whole organs by mass spectrometry, blood has to be cleared from
the vessels of those organs, as it would corrupt the results by its own sphingolipid content.
Therefore, mice were transcardially perfused with PBS prior to the dissection of organs
for mass spectrometric analyses. First, mice were anesthetized with isoflurane, laid on
their back, cleaned with 70% ethanol and the thoracic cavity was opened. Then, a 21G
butterfly needle tubed to a 50ml syringe containing pre-chilled PBS was carefully inserted
into the left ventricle and fixed, before the right atrium was incised with scissors. With
gentle pressure, the mouse was perfused with PBS until the eux from the atrium became
transparent and organs like the lungs, liver and kidney turned pale. Afterwards, organs
could be removed for mass spectrometric analyses.
3.2.1.6 Generation of bone marrow chimeras The generation of bone marrow
chimeras was performed in cooperation with the Institute for Experimental Immunol-
ogy (IEI) at the University hospital Bonn and conducted by Dr. Elisabeth Mettke. There-
fore, this technique is just briefly described. Donor mice were sacrificed by cervical dis-
location, bones were removed as described in 3.2.1.4 and bone marrow cells were isolated
as described in 3.2.4.5. Recipient mice were anesthetized by an i.p. injection of ketamine
(93.75mg/kg body weight) and xylazine (6.225mg/kg body weight) in 150 µl saline, fol-
lowed by an irradiation with 7Gy from a Caesium-137 source for 4min. After 4 h, recipient
mice received 0.5  1 x 107 bone marrow cells from the donor mice in 100µl saline via i.v.
injection. 10 weeks post reconstitution, chimeric mice were analyzed.
3.2.1.7 Thymus transplantation Thymus transplantation experiments were
performed in cooperation with the Institute for Experimental Immunology (IEI) at the
University hospital Bonn and the surgeries were conducted by Katarzyna Jobin. Therefore,
this technique is just briefly described. After neonatal donor mice were sacrificed by
decapitation, the thymi were removed as described in 3.2.1.4, the lobes were separated
and stored in pre-chilled PBS on ice until further processing. Male adult recipient mice
were anesthetized with isofluorane and the kidney was accessed by a small incision in the
right flank. Single thymus lobes of donor mice were gently transferred under the kidney
capsule of the recipient. After the incision was closed, the recipients received tramal as
analgesic for 2 further days. 4 to 5 weeks post transplantation, thymic grafts were analyzed.
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3.2.2 Molecular biology
3.2.2.1 Agarose gel electrophoresis Nucleic acids were separated according to their
size via agarose gel electrophoresis. First, agarose was added to TAE buffer (1 - 3% (w/v),
depending on the size of the nucleic acid that is to be separated) and solved via heating
in a microwave. Afterwards, ethidium bromide was added (final concentration: 0.2 µg/ml)
and the mixture was allowed to polymerize in special agarose gel cast chambers. Combs
with defined numbers of tooths were inserted into the polymerizing gel to form pockets,
in which the samples of interest could be loaded after the gel has hardened. Next, the
polymerized gels were transferred into electrophoresis chambers, which contained TAE
as running buffer, the combs were removed and the samples that have been previously
mixed with 6x loading dye were loaded into the gel pockets. Additionally, a DNA ladder,
a mixture of DNA fragments of defined sizes, was loaded into one pocket, enabling the
determination of the size of the nucleic acids in the samples. Dependent on the size of the
gels, electrophoretic separations were performed for 30  60min at 60 - 120V. Afterwards,
nucleic acids were visualized in a transilluminator at a wavelength of 230 nm.
1x TAE Component Final concentration
Tris 40mM
Acetic acid 40mM
EDTA 0.5 mM
A. bidest
6x loading dye Component Final concentration
Bromphenol blue 0.25%
Xylene cyanol 0.25%
Glycerol 30%
A. bidest
3.2.2.2 Isolation of RNA The isolation of RNA was performed using TRIzol reagent
according to the manufacturer's instructions. The cells of interest were harvested and
pelleted by centrifugation (5min at 300 x g and RT). The supernatant was discarded and
the pellet was resuspended in TRIzol reagent to homogenize the cells (1ml TRIzol for 0.5
 1 x 107 cells and 0.5ml TRIzol for less than 0.5 x 107 cells). Then, the samples were
either stored at -80°C to continue isolation at later time points or immediately processed
by incubating them for 5min at RT. Afterwards, chloroform was added to the samples
(0.2ml per 1ml TRIzol) and the tubes were shaken for 15 s. After 3min incubation at room
temperature, samples were centrifuged for 1min at 12000 x g and 4°C. The RNA-containing
aqueous phase (upper phase) was transferred into a new 1.5ml reaction tube and mixed
with 2-propanol (0.5ml per 1ml TRIzol), followed by an incubation for 10min at RT. The
samples were centrifugedfor 10min at 12000 x g and 4°C, the supernatant was discarded
and the RNA pellet was rinsed once by adding 70% ethanol (1ml per 1ml TRIzol). After a
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centrifugation for 5min at 7500 x g and 4°C, the supernatant was discarded again and the
RNA pellet was air dried. Finally, the RNA pellet was resuspended in 20  40 µl RNase-free
water and the samples were incubated for 1 - 2min at 55°C in heat block to dissolve the
RNA. Isolated RNA samples were either further processed or stored at -80°C.
To extract RNA from tissues, freshly isolated or frozen samples were transferred into 2ml
micro tubes with an appropriate amount of acid-washed glass beads. 1ml TRIzol per
50 - 100mg sample weight was added to the tubes and samples were homogenized using
a Precellys tissue homogenizer. The subsequent steps were carried out according to the
above-mentioned protocol.
3.2.2.3 DNaseI digestion of RNA samples To remove contaminating genomic
DNA in RNA preparations, samples were treated with DNaseI. Therefore, 2.4 µl 10x DNa-
seI buffer and 2µl DNaseI were added to 20µl of each RNA preparation and samples
were incubated for 20min at 37°C. Afterwards, 2µl 50mM EDTA was added (prevents
RNA hydrolysation[200] and samples were incubated for 10min at 75°C to inactivate the
DNaseI.
3.2.2.4 Measuring RNA concentrations The concentration of RNA was measured
in a Nanodrop spectrophotometer. Based on the absorbance at 280 nm and on the ratio of
the absorbance at 280 and 260 nm (280/260) the amount of RNA per µl and the purity of
the sample were calculated, respectively.
3.2.2.5 cDNA synthesis Isolated RNA (up to 1 µg per sample) was transcribed into
cDNA using the High-Capacity cDNA Reverse Transcription Kit from Applied Biosystems
(Thermo Fischer). According to the manufacturer's instructions, the following components
and thermal cycler conditions were used:
Reaction setup Component (concentration) Volume for 1x reaction [µl]
10x RT Buffer 2
25x dNTP Mix (100mM) 0.8
10x RT Random Primers 2
MultiScribe Reverse Transcriptase 1
RNA ≤1 µg
A. bidest Ad 20
Σ 20
Thermal cycler program Step Temperature [°C] Time [hh:mm:ss] Cycles
1 25 00:10:00 1x
2 37 02:00:00 1x
3 85 00:05:00 1x
4 4 ∞ -
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3.2.2.6 RT-PCR with SYBR green Gene expression was analyzed by SYBR green-
based semi-quantitative real time PCR using the KAPA SYBR FAST qPCR Master Mix
for Bio-Rad iCycler or the iTaq Universal SYBR Green Supermix from Bio-rad according
to manufacturer's instructions. These master mixes provided all essential components for
RT-PCR except for the cDNA template and the primers which target the transcripts of
interest. For one reaction, the reagents were mixed in the following ratios:
Reaction setup Component (concentration) Volume for 1x reaction [µl]
cDNA 0.5
Forward Primer (10mM) 0.2
Reverse Primer (10mM) 0.2
2x Master Mix 5
A. bidest 4.1
Σ 10
All RT-PCRs were performed in sealed 96-well plates in an CFX thermal cycler from
Bio-Rad with the following conditions:
Thermal cycler program Step Temperature [°C] Time [mm:ss] Cycles Phase
1 95 03:00 1x Denaturation
2 95 00:10 Denaturation
2 58 00:30 40x Annealing
2 72 00:30 Elongation
2 72 - Measurement
3 95 - 55 00:30 per step 1x Melting Curve
4 4 ∞ - Hold
Relative expression of genes of interests was calculated in relation to the expression Gapdh
as housekeeping gene on the basis of the 2-(ΔCt) method.
To detect the formation of unspecific amplicons, which would corrupt gene expression
measurements, melting curve analyses were performed at the end of a successful RT-PCR
run. Additionally, specificity of the RT-PCR was verified by loading the samples onto an
agarose gel to analyze if the amplicons have the expected size.
3.2.3 Biochemistry
3.2.3.1 Protein extraction The cells of interest were harvested and centrifuged at
300 x g and 4°C for 5min. The supernatant was discarded and the cells were rinsed once
with ice-cold PBS, followed by another centrifugation at 300 x g and 4°C for 5min. The
supernatant was discarded again and the cells were resuspended in ice-cold RIPA lysis
buffer containing pre-added phosphatase inhibitors and freshly added protease inhibitors
(30 - 40 µl lysis buffer per 2 x 106 cells (lymphocytes)). Samples were incubated for 5min
on ice, before they were sonicated (10 pulses at 35 - 70%) and centrifuged for 5min at
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16000 x g and 4°C. Afterwards, the supernatant was transferred into a new 1.5ml reaction
tube and kept at 4°C for further processing or stored at -20°C. The pellet was discarded.
To isolate proteins from tissues, freshly isolated or frozen samples were minced with a
small pestle in the presence of ice-cold RIPA lysis buffer containing pre-added phosphatase
inhibitors and freshly added protease inhibitors within a 1.5ml reaction tube. The subse-
quent steps were carried out according to the above-mentioned protocol.
RIPA lysis buffer Component Final concentration
NaCl 150mM
preprared
Triton X-100 1%
Sodiumdeoxycholate 0.5%
SDS 0.1%
Tris 50mM
Glycerol phosphate 10mM
Sodium fluoride 50mM
Sodium pyrophosphate 5mM
Sodium orthovanadate 1mM
Antipain 2 µg/ml
freshly added
phosphatase
inhibitors
Aprotinin 10 µg/ml
Benzamidine 1mM
Leupeptin 10 µg/ml
PMSF (saturated
solution)
1:1000
3.2.3.2 Determination of protein concentration The protein concentration of
lysates was determined using the BCA Protein Assay Kit from Thermo Scientific according
to manufacturer's instructions. This method is based on the linear dependence between the
reduction of Cu2+ to Cu1+ by proteins in alkaline milieu and the subsequent colorimetric
detection of Cu1+ by bicinchoninic acid, which can be photometrically determined by
measuring the absorbance at 562 nm. In brief, 3 µl per sample were transferred into a 96-
well plate, before 200 µl BCA reagent (50:1 Solution A:Solution B) was added to each well.
Additionally, a BSA standard curve (0, 0.125, 0.25, 0.5, 1, 2, 4mg/ml; 3 µl per standard)
was also pipetted into the plate and mixed with 200 µl BCA reagent. After the plate was
incubated for 10min at 65° C, the absorbance at 562 nm was measured in a tecan plate
reader and the protein concentration was calculated according to the BSA standard curve.
3.2.3.3 Preparation of lysates for SDS-PAGE After the protein concentration was
successfully determined, the required volume was transferred into a new 1.5ml reaction
tube and an adequate amount of 5x sample buffer was added. Then, the samples were
incubated for 5min at 95°C to effectively denature the proteins, short spun to collect the
lysates at the bottom of the tube and loaded onto an SDS gel.
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5x sample buffer Component Final concentration
Tris-HCl 100mM
SDS 4%
Bromphenol blue 0.1%
Glycerol 20%
DTT 200mM
3.2.3.4 SDS-PAGE Via SDS-PAGE, proteins were electrophoretically separated ac-
cording to their molecular weight. In contrast to nucleic acids, proteins can have complex
superior structures (secondary, tertiary and quaternary) and a variable ratio of mass and
charge. To enable an electrophoretic separation that only depends on the molecular weight,
both of these factors need to be graded between the proteins in a lysate. SDS is an an-
ionic detergent that performs either tasks. On the hand, it binds proteins in a direct
proportionality to their mass (1.4 g SDS per g protein). Thus, the negative charge of the
SDS masks the intrinsic charge of the protein, constituting a constant ratio of mass and
charge. On the other hand, binding of SDS to proteins causes their denaturation, as the
superior structures become unfolded. In this study discontinuous SDS gels were used for
all experiments. These gels consist of an upper gel (stacking gel) with low pH (6.8) and
low acrylamide concentration (5%) and a lower gel (resolving gel) with a higher pH (8.8)
and higher acrylamide concentration (8 - 12%). Whereas the stacking gel concentrates
the proteins in a sharp band, allowing their simultaneous entry into the resolving gel, the
latter actually separates the proteins according to their molecular weight. Per sample, 10
or 20µg protein in sample buffer (3.2.3.3) were loaded onto the SDS gels. Electrophoresis
was performed in running buffer at 80V until the proteins reached the resolving gel and
subsequently at 120V until the dye front leaked into the buffer.
Discontinuous SDS-Gels Component Stacking Gel [ml] Resolving Gel [ml]
H2O 0.68 1.6  2.3
Tris-HCl (1M, pH 6.8) 0.13 -
Tris-HCl (1.5M, pH 8.8) - 1.3
Acrylamide/
Bisacrylamide (30 %)
0.17 1.3  2.0
SDS 10% 0.01 0.05
APS 10% 0.01 0.05
TEMED 0.001 0.002
Σ 1ml 5ml
10x running buffer Component Final concentration
Tris 0.25 M
Glycin 2.5M
SDS 1%
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3.2.3.5 Western Blot Separated proteins were transferred from SDS gels onto nitro-
cellulose membranes by Western Blotting. First, the SDS gel, a nitrocellulose membrane,
6 Whatman papers and two sponges were drenched in cooled transfer buffer. Then, the
SDS gel and the nitrocellulose membrane were compressed against each other in a mini
gel holder cassette by 3 Whatman papers and one sponge on each side. The cassette was
placed into a blotting chamber filled with cooled transfer buffer and the transfer was per-
formed for 2 h at 80V and 6°C. The success of the transfer was verified by incubating the
membrane for 1 - 2min in Ponceau red solution. Ponceau S is a dye that reversibly stains
proteins on nitrocellulose or PVDF membranes. After incubation in Ponceau red solution,
the membrane was rinsed with TBST until an adequate contrast between the protein bands
and the background was achieved.
1x transfer buffer Component Final concentration
Glycin 192mM
Tris 25mM
Methanol 20%
1x TBST Component Final concentration
Tris 50mM
NaCl 150mM
Tween-20 0.05%
Ponceau Red Component Final concentration
Acetic acid 5%
Ponceau S 0.1%
3.2.3.6 Immunodetection of proteins Specific proteins on nitrocellulose membranes
were detected via a two-stage antibody staining and a subsequent chemoluminescence
reaction. First, the membranes were rinsed once with TBST, followed by incubation with
5% milk powder in TBST for 1 h at RT to block unspecific binding sites. Next, the blocked
membranes were incubated overnight at 4°C with a primary antibody, which was diluted in
5% milk powder in TBST and directed against the protein of interest. On the next day, the
membranes were rinsed 3 times for 5 - 10min with TBST and subsequently incubated for
1 h at RT with the secondary antibody that was coupled to HRP and directed against the
host species of the primary antibody. Afterwards, the membranes were rinsed again 3 times
for 5 - 10min with TBST. Finally, the membranes were moistened with freshly prepared
ECL solution (1:1 mixture of solution A and solution B) and placed in autoradiography
cassettes. In the presence of H2O2, the HRP now catalyzed the oxidation of luminol (both
components were included in the ECL solution), emitting chemoluminescent signals that
were detected using photosensitive films. The exposure time was adjusted to the signal
strength and films were developed manually or using a developing machine.
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3.2.3.7 Regeneration of membranes (Stripping) In most cases, more than one
protein was to be detected sequentially on a single nitrocellulose membrane. To remove
primary and secondary antibodies from previous immunostainings, the membranes were
covered with RT stripping buffer in a glass dish and placed on a heat plate that was
adjusted to 150°C. After 15 - 20min, the membranes were removed from the stripping
buffer and intensively rinsed with TBST (5 - 10x for 5 - 10min). Afterwards, membranes
were ready to be blocked and stained again.
Stripping buffer (pH 6.8) Component Final concentration
SDS 2%
Tris (pH 6.8) 62.5mM
β-Mercaptoethanol 100mM
3.2.3.8 Extraction and mass spectrometric quantification of sphingolipids The
extraction and mass spectrometric quantification of sphingolipids was performed by Prof.
Dr. Markus Gräler (Department of Anesthesiology and Intensive Care Medicine, Center for
Sepsis Control and Care (CSCC), and the Center for Molecular Biomedicine (CMB), Jena
University Hospital, Jena, Germany). In brief, tissue samples were mechanically homog-
enized and (sphingo-)lipids were isolated via methanol/chloroform extraction before they
were quantified using liquid chromatography coupled to triple-quadrupole mass spectrom-
etry (LC/MS/MS). A detailed description of the method can be found in [1, 201, 202].
3.2.4 Cell biology
3.2.4.1 Isolation of PBMCs PBMCs were isolated via density gradient centrifuga-
tion. The diluted blood (3.2.1.3) was carefully layered onto 3ml lymphoprep density cen-
trifugation medium in a 15ml falcon tube and centrifuged for 20min at 800 x g and RT.
In order to protect the gradient during the deceleration process at the end of the centrifu-
gation, the brakes of the centrifuge were switched off. The PBMC containing interphase
was carefully harvested, transferred into a new 15ml falcon tube, rinsed with 10ml PBS
and centrifuged for 10min at 300 x g and 4°C. The supernatant was discarded and the
pellet was resuspended in another 10ml PBS, followed by a centrifugation for 10min at
120 x g and 4° C. During this slow spin, the PBMCs were pelleted at the bottom of the
tubes, whereas contaminating platelets,which were unintentionally co-harvested, remain
in suspension for the most part. The (platelet-rich-)supernatant was discarded and the
PBMCs were resuspended in 1 - 2ml PBS and stored on ice until further processing.
3.2.4.2 Isolation of lymphocytes from thymi, spleens and lymph nodes Lym-
phocyte single cell suspensions from thymi, spleens and lymph nodes were prepared by
placing the single organs in a 40 µm cell strainer within a 10 cm cell culture dish that was
filled with cooled PBS. Then, the organs were passed with gentle pressure through the cell
39
3 MATERIALS AND METHODS
strainer using the plunger of a 10ml syringe. The strainer was rinsed once with cooled
PBS and the single cell suspension was transferred into new falcon tubes (15ml for lymph
nodes and 50ml for thymi and spleens), followed by a centrifugation for 10min at 300 x g
and 4°C. Lymphocytes from thymi and lymph nodes were resuspended in cooled PBS and
counted with a Neubauer chamber. Lymphoctes from spleens were resuspended in RBC
lysis buffer (3ml per spleen) and incubated for 2min at RT. In this hypotonic buffer, ery-
throcytes, which constitute a large fraction in single cell suspensions from spleens, break,
whereas the lymphocytes remain intact. Lysis was stopped by the addition of 45ml cooled
PBS. Cellular debris, which occurred during the mechanical disruption of the spleen and
the subsequent RBC lysis, was removed by transferring the cell suspension through a 70µm
cell strainer into a new 50ml falcon tube, followed by a centrifugation for 5min at 300 x g
and 4°C. After the supernatant was discarded, the cells were resuspended in cooled PBS
and counted with a Neubauer chamber.
3.2.4.3 Isolation of innate immune cells from the thymus Thymic innate im-
mune cells were isolated via enzymatic digestion of whole thymi applying the same protocol
that was used for the isolation of TSCs (3.2.4.4).
3.2.4.4 Isolation of thymic stromal cells (TSCs) Isolation of TSCs was performed
via enzymatic digestion of thymic tissue according to [203]. In brief, thymi were cut into
small pieces and transferred in a new 50ml falcon tube, filled with 20ml pre-chilled RPMI.
Thymocytes were released from the fragments via repeated resuspension with a 20ml
serological pipette. After the fragments had settled, the thymocyte rich supernatant was
discarded and the fragments were transferred into a new 1.5ml reaction tube containing
600 - 700 µl digestion medium (RPMI containing a mix of liberase (TM, 0.5WU/ml) and
DNaseI (50 - 375U/ml)), followed by an incubation at 37°C for 10 - 15min. Next, the
fragments were gently agitated using a 1000 µl pipette tip. The fragments were allowed to
settle and the supernatant was transferred into a 50ml falcon tube containing 10ml stop-
ping buffer (PBS with 0.02%BSA and 5mM EDTA) to prevent further digestion. Then,
fresh digestion medium was added to the remaining fragments and the cycle was repeated
until the tissue was completely disaggregated (typically 2 - 3 times). The supernatants
that were harvested in between, were all pooled in the 50ml tube containing the stopping
buffer. Eventually, cells were pelleted via a centrifugation at 500 x g for 5min at 4°C and
resuspended in fresh PBS. After counting the cells with a Neubauer chamber, TSCs were
further enriched by depletion of CD45+ cells via MACS (3.2.4.7).
3.2.4.5 Isolation of bone marrow cells from tibia and femur To isolate bone
marrow cells from tibia and femur, the bones were opened at both ends with a bone
scissors. Next, the bone marrow was flushed out of the bones into a 10 cm cell culture
dish using a 10ml syringe filled with cooled PBS and equipped with a 27G needle. The
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bone marrow single cell suspension was transferred into a 50ml falcon tube, rinsed with 20
- 30ml cooled PBS and centrifuged for 10min at 300 x g and 4°C. After the supernatant
was discarded, the cells were resuspended in cooled PBS and counted with a Neubauer
chamber.
3.2.4.6 Cell counting and calculations Cells in suspension were counted using a
hemocytometer (Neubauer chamber). In a hemocytometer, a microscope slide with a grid
and a cover slip form a space of specific volume that can be filled with a cell suspension
of interest. The cells in the grid can be counted with a microscope and the number of
cells per ml can be calculated via the known volume of the liquid column above the grid.
The grid contains four large squares that are composed of 16 small squares, respectively.
Generally, cells in 2 - 4 large squares were counted and the the cell number per ml was
calculated according to the following formula:
N = nBS · 1VBS ·D = nBS · 10.1mm3 ·D = nBS · 10
4
1ml ·D
N Cell number [1/ml]
n Counted cells
BS Number of counted big squares
VBS Volume of one big square (0.1mm
3)
D Dilution factor
The numbers of lymphocyte subpopulations in thymus, spleen, lymph node, blood and
bone marrow, were calculated from their relative frequencies, which were obtained by flow
cytometric analyses (see 3.2.4.8), and the total cell numbers in the respective compart-
ments, which were obained by counting (see above).
3.2.4.7 Magnetic activated cell sorting (MACS) Via magnetic activated cell sort-
ing, specific cell populations can be isolated out of single cell suspensions. In general, two
different separation strategies can be applied. For positive selection, the cells of interest are
stained with biotinylated antibodies and magnetic anti-biotin microbeads. Afterwards, the
samples are transferred into MACS column that is placed into a magnetic field. Whereas
all unstained stains pass through the column, the stained cells are retained in the magnetic
field and can be flushed after the column has been removed from the magnetic field. For
negative selection (depletion), all unwanted cells are stained with biotinylated antibodies
and magnetic anti-biotin microbeads, followed by the same separation method as for the
positive selection. In both cases, single cell suspensions were incubated with biotinylated
antibodies according to manufacturer's instructions (generally ≤ 0.25µg per 106 cells in
100µl volume for 20min at 4°C) to label the wanted/unwanted cells. Afterwards, cells were
rinsed with 2ml cooled MACS buffer per 107 cells and centrifuged for 5min at 300 x g and
4°C. After the supernatant was discarded, cells were resuspended in 80µl cooled MACS
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buffer per 107 cells and 20 µl anti-Biotin microbeads per 107 cells were added to the sam-
ples, followed by an incubation for 10min at 4°C. Cells were rinsed again with 2 ml cooled
MACS buffer per 107 cells, centrifuged for 5min at 300 x g and 4°C and resuspended in
500µl cooled MACS buffer per 108 cells. The subsequent magnetic separation was ei-
ther performed manually or automatically using an autoMACS pro separator according to
manufacturer's instructions.
In some experiments, cells were prepared for magnetic separation by labelling them with
magnetic microbeads that directly bind to specific surface markers (e.g. anti-CD45 mi-
crobeads). In these cases, the staining conditions, as well as the subsequent steps are
comparable to the incubation with anti-Biotin microbeads.
MACS buffer Component Final concentration
EDTA 2mM
BSA 0.5%
PBS
3.2.4.8 Flow cytometry Via flow cytometry, various parameters (e.g. the size, the
granularity or the (surface) expression of proteins) of single cells or other small particles can
be analyzed simultaneously. In general, the cells of a single cell suspension become arranged
in succession by a technique called hydrodynamic focusing, before they pass laser beams.
Dependent on the size and the granularity of the cells, the light is differentially absorbed
and scattered, which is measured by two detector systems. The forward scatter detector
(FSC) is arranged in line with the laser beams and measures the light that passes through
the cells. The bigger the cells are the less light reaches the detector. Thus, the FSC detector
gives information about the cell size. Contrarily, the sideward scatter detector (SSC) is
positioned in a defined angle to the laser beams and measures the light that is scattered by
the cells. As this parameter is dependent on e.g. the amount of granules or other membrane
compartments, the SSC detector gives information about the internal complexity of the
cells. Furthermore, the lasers are able to excite several fluorochromes simultaneously, whose
emission is separated from each other by specific band pass filters and finally measured by
an additional set of detectors. Thus, extra- or intracellular proteins can be stained with
fluorochrome-conjugated antibodies and their expression is subsequently analyzed via flow
cytometry.
3.2.4.9 Staining of cell surface proteins for flow cytometric analyses To stain
cell surface proteins for flow cytometric analyses, 0.5 - 1 x 106 cells were harvested and
transferred into special tubes for flow cytometry and rinsed with 1ml cooled PBS. After
a centrifugation for 5min at 300 x g and 4°C, the supernatant was discarded and the cells
were resuspended in 100 µl PBS containing the antibodies against the proteins of interest
(the amounts of antibodies were calculated according to the manufacturer's instructions)
and incubated for 20min at 4°C in the dark. Next, cells were rinsed with 1ml cooled PBS,
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centrifuged for 5min at 300 x g and 4°C, resuspended in 200 - 500 µl cooled PBS and stored
briefly at 4°C until analysis on a Canto II or an LSR flow cytometer. In some experiments,
PI (200 ng per sample) was added to the cells before they were measured. PI stains dead
and dying cells as it passes through porous membranes and binds to DNA. Thus, it was
possible to consider only living cells for analysis.
3.2.4.10 Staining of intracellular proteins for flow cytometric analyses Intra-
cellular proteins were stained using the Foxp3/Transcription Factor Staining Buffer Set
from eBioscience according to manufacturer's instructions. First, 1 - 5 x 106 cells were sur-
face stained as described above. After the final wash, the supernatant was discarded and
the cells were pulse-vortexed in 1ml PBS containing fixable viability dye from eBioscience
(1:1000), followed by an incubation for 30min at 4°C in the dark. Marking the dead cells
with a fixable dye at this stage is absolutely important, as the subsequent fixation kills all
cells, preventing the setting of a classical living gate by FSC/SSC characteristics during
flow cytometric analysis. Next, cells were rinsed with 1 ml cooled PBS, centrifuged for
10min at 300 x g and 4°C. After the supernatant was discarded, the cells were vortexed
in the residual buffer while 1ml FoxP3 fixation/permabilization working solution was si-
multaneously added. Cells were incubated for 45min at 4°C in the dark, rinsed with 2ml
1x permeabilization buffer and centrifuged for 10min at 300 x g and 4°C. The supernatant
was discarded and the cells were resuspended in 100 µl 1x permeabilization buffer contain-
ing the antibodies against the proteins of interest, followed by an incubation for 30min
at 4°C in the dark. If the antibody against the protein of interest was conjugated to a
fluorochrome, the cells were rinsed two times with 2ml 1x permeabilization buffer and cen-
trifuged for 10min at 300 x g and 4°C, before they were resuspended in 200 - 500µl cooled
PBS and stored briefly at 4°C until analysis on a Canto II or an LSR flow cytometer. If the
antibody against the protein of interest was unconjugated, the cells were rinsed once with
2ml 1x permeabilization buffer, centrifuged for 10min at 300 x g and 4°C and resuspended
in 100 µl 1x permeabilization buffer containing the secondary antibodiy, followed by an
incubation for 30min at 4°C in the dark. Finally, the cells were rinsed two times with 2ml
1x permeabilization buffer and centrifuged for 10min at 300 x g and 4°C, before they were
also resuspended in 200 - 500 µl cooled PBS and stored briefly at 4°C until flow cytometric
analysis.
3.2.4.11 Annexin V staining Apoptotic cells were detected using the Annexin V
Apoptosis Detection kit from eBioscience according to manufacturer's instructions. First,
1 - 5 x 105 cells were harvested, rinsed with 1ml PBS and centrifuged for 5min at 300 x g
and RT. After the supernatant was discarded, the cells were washed again with 1ml 1x
binding buffer and centrifuged at the same conditions. Next, the cells were resuspended
in 100µl binding buffer containing 5 µl fluorochrome-conjugated Annexin V and incubated
for 15min at RT in the dark. Before the cells were analyzed in a flow cytometer, they were
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rinsed with 2ml 1x binding buffer, centrifuged for 5min at 300 x g and 4°C and resuspended
in 200µl 1x binding buffer containing 5µl PI.
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4 Results
4.1 CERS2 facilitates S1P-mediated thymic egress of mature SP thy-
mocytes into the circulation
To be able to induce effective immune responses against a broad range of pathogens,
the adaptive immune system depends on an ever-changing peripheral TCR repertoire,
which requires the constant production of new T cells in the thymus. After finishing their
developmental program, mature SP thymocytes leave the thymus and enter the circula-
tion along a chemoattractive S1P gradient to become part of the peripheral T cell pool.
Although it is known that this S1P gradient results from low S1P levels in the thymus
parenchyma and high S1P levels in the perivascular space and in the blood, its exact ar-
chitecture as well as the regulatory mechanisms that control S1P-mediated thymic egress
are insufficiently understood [26, 79].
We hypothesized that the CERS2-dependent regulation of the S1P precursor sphingosine
might contribute to the maintenance of the S1P gradient between thymus and blood and
thus facilitates the entry of terminally differentiated thymocytes into the periphery. In
the first part of the present study, this hypothesis was tested by analyzing the shape of
the thymic S1P gradient and the efficiency of thymic egress in wild type (Cers2+/+) and
CERS2-deficient mice (Cers2gt/gt).
4.1.1 Introductory remarks concerning the use of CERS2-deficient mice for
the analysis of S1P-dependent thymic egress
The Cers2gt strain derives from an ES cell clone, in which the Cers2 locus was mutated via
random insertion of the gene trap vector ROSAFARY(see 3.1.10). Mice that are homozy-
gous for this gene trap mutation (Cers2gt/gt) have no functional Cers2 allel and totally lack
expression of CERS2, as shown by RT-PCR and immunoblot analysis (Figure 4.1A - D).
The Cers2gt/gt mice and the appropriate wild type controls (Cers2+/+) that were used in
this study were generated by intercrossing Cers2+/gt mice. CERS2-deficient mice exhibit
severe phenotypes, such as decreased body size and increased mortality, which reduces the
frequency of Cers2gt/gt mice within litters of Cers2+/gt intercrossings already 3 weeks after
birth from the expected 25% (Mendelian ratio) to below 10% (Figure 4.1E - G and [161]).
However, a sufficient amount of Cers2gt/gt mice reached adulthood and could be analyzed
in this study.
Worthy of note is that the reduced body size of Cers2gt/gt mice would skew the quantifi-
cation of absolute cell numbers, which are integral parts of many analyses of the present
study, towards generally fewer cells in CERS2-deficient mice. To overcome this bias, cell
counts of Cers2gt/gt mice and of respective wild type controls are shown in two different
ways throughout this manuscript. On the one hand, the results are presented as unmodified
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Figure 4.1: Basal characteristics of Cers2gt/gt mice. (A - C) Expression of Cers1 - 6 in bone marrow
(A), thymocytes (B) and splenocytes (C) of female wild type (+/+, white bars) and CERS2-deficient mice
(gt/gt, black bars) was analyzed by RT-PCR (N = 3 mice per genotype). Expression is shown relative to
that of Gapdh. Bar graphs represent means + SD. Data are pooled from 2 experiments, in which 1 - 2 mice
per genotype were analyzed. (D) Levels of CERS2 and actin in lysates of bone marrow, thymi, thymocytes,
spleens and splenocytes of one female wild type and one female CERS2-deficient mouse were determined
by immunoblot-analysis. Data represent a single experiment. (E) Representative photo of an adult male
wild type mouse and a CERS2-deficient litter mate. (F) Weights of female (N = 14 mice per genotype) and
male (N = 9 - 16 mice per genotype) wild type (+/+, white dots) and CERS2-deficient (gt/gt, black dots)
mice at young adulthood (8 - 14 weeks). Dots represent individual mice (Unpaired t-test; ***P<.001).
Data are pooled from individual experiments, in which 1 - 2 mice per genotype were analyzed, respectively.
(G) Frequencies of wild type (+/+), heterozygous (+/gt) and CERS2-deficient mice (gt/gt) at the age of
weaning (3 - 4 weeks after birth), originating from heterozygous parental intercrossings (+/gt x +/gt). In
total, 162 newborn female (red bars) and 190 newborn male (blue bars) mice were analyzed. Bar graphs
represent the percentage of the genotypes within all females and males, respectively. The data of panel F
were already published in [1].
numbers (shown as cell count and denoted as raw data). On the other hand, the results
are presented as numbers that have been normalized to the average mouse weights of wild
type and CERS2-deficient mice (shown as cell count per g mouse and denoted as weight
corrected data). For weight correction, the following average weights were used: male wild
type mice = 23.9 g, male CERS2-deficient mice = 15.8 g, female wild type mice = 18.6 g
and female CERS2-deficient mice = 11.2 g (Figure 4.1F). The descriptions in the main
text of the results part refer exclusively to the weight corrected data, unless indicated
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otherwise. All figures, in which the results are shown in this dual manner can be found in
the following list: Figure 4.2, Figure 4.4A and B, Figure 4.5A and B, Figure 4.6D and F,
Figure 4.17B and C.
Additionally, it should be remarked that the thymi of female CERS2-deficient mice har-
boured generally fewer cells than their wild type controls, while the overall number of
thymocytes in male CERS2-deficient mice was even slightly increased compared to male
wild type controls (Figure 4.2). A similar gender-specific phenotype was not found in any
other lymphoid or non-lymphoid organ of CERS2-deficient mice (data not shown). As a
consequence of this thymus-specific sexual dimorphism, quantifications of thymocyte sub-
populations from Cers2gt/gt mice, which are key read-outs for the present study, are shown
separately for male and female mice throughout this manuscript (affected figures include
Figure 4.4, Figure 4.5 and Figure 4.17). The results of all other analyses are not separated
for genders.
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Figure 4.2: CERS2-deficiency reduces thymocyte numbers in female but not in male mice. Quantification
of total thymocyte counts in thymi of female (N = 14 mice per genotype) and male (9 - 10 mice per
genotype) wild type (+/+, white dots) and CERS2-deficient (gt/gt, black dots) mice. Results are shown
as counts (left, raw data) and as counts per g mouse (right, weight corrected data). For weight correction,
total counts were normalized to the average mouse weights of female and male wild type and CERS2-
deficient mice, respectively, (see 4.1.1). Dots in scatter plots represent individual mice and black lines
represent means (Unpaired t-test; **P<.01, ***P<.001). Data are pooled from individual experiments, in
which 1 - 2 mice per genotype were analyzed.
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4.1.2 CERS2-deficiency impairs thymic egress
Based on several groundbreaking studies, thymic emigration along the S1P gradient is
currently regarded as a two-stage process. First, terminally differentiated thymocytes are
chemotactically recruited from the medulla into the perivascular space by the intrathymic
part of the S1P gradient. Second, the thymocytes transmigrate from the perivascular space
into the circulation in response to the steep S1P gradient that exists between thymus and
blood [79].
To investigate if CERS2-deficiency affects emigration of terminally differentiated thymo-
cytes into the periphery, frequencies and total numbers of immature and mature SP thy-
mocytes in thymi of wild type and CERS2-deficient mice were determined by flow cy-
tometry. Whereas immature cells are still in the process of negative selection and are
consequently not allowed to leave the thymus, mature SP thymocytes have completed
negative selection, express S1PR1 and are thus competent to emigrate via the S1P gra-
dient into the circulation (see 1.3.2 and [89]). Immature and mature SP thymocytes were
discriminated on the basis of differential surface expression of CD62L and CD69 (immature
= CD62Llow/CD69high and mature CD62Lhigh/CD69intermediate.
Flow cytometric analysis revealed that deficiency of CERS2 in male mice led to a significant
increase in the frequencies and numbers of mature CD4+/CD8- and CD4-/CD8+ thymo-
cytes, but did not affect the numbers of immature SP thymocytes (Figure 4.3, Figure 4.4A
and Figure 4.5A). The same observation was made in females, except that the difference in
the numbers of mature SP thymocytes between Cers2+/+ and Cers2gt/gt mice did not reach
statistical significance (Figure 4.4B and Figure 4.5B). Most likely, the increase in the num-
bers of mature SP thymocytes in female CERS2-deficient mice is less robust than in males,
because it is partially masked by the general reduction in thymic cellularity (Figure 4.2).
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Figure 4.3: Representative pictures of flow cytometric identification of immature (CD62Llow/CD69high)
and mature (CD62Lhigh/CD69intermediate) CD4+/CD8- and CD4-/CD8+ thymocytes in thymi of male
wild type (+/+) and male CERS2-deficient mice (gt/gt). Numbers indicate percentages of subpopulations
within the parental populations. This figure was taken from [1].
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Figure 4.4: Selective accumulation of
mature CD4+/CD8- thymocytes in thymi
of CERS2-deficient mice. (A and B) Fre-
quencies and counts of immature and ma-
ture CD4+/CD8- thymocytes in thymi of
male (A; N = 7 - 8 mice per genotype)
and female (B; N = 5 mice per genotype)
wild type (+/+, white bars and dots) and
CERS2-deficient (gt/gt, black bars and
dots) mice were determined by flow cy-
tometry. Results are shown as frequencies
(upper panels), counts (middle panels,
raw data) and counts per g mouse (lower
panel, weight corrected data). For weight
correction, total counts were normalized
to the average mouse weights of female
and male wild type and CERS2-deficient
mice, respectively, (see 4.1.1). Results are
separated for genders as described above
(see 4.1.1). Dots in scatter plots repre-
sent individual mice and black lines rep-
resent means; bar graphs represent means
+ SD (Unpaired t-test; *P<.05, **P<.01,
***P<.001). Data are pooled from indi-
vidual experiments, in which 1 - 2 mice
per genotype were analyzed. The data of
panel A were already published in [1]
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Figure 4.5: Selective accumulation of
mature CD4-/CD8+ thymocytes in thymi
of CERS2-deficient mice. (A and B) Fre-
quencies and counts of immature and ma-
ture CD4-/CD8+ thymocytes in thymi of
male (A; N = 7 - 8 mice per genotype)
and female (B; N = 5 mice per genotype)
wild type (+/+, white bars and dots) and
CERS2-deficient (gt/gt, black bars and
dots) mice were determined by flow cy-
tometry. Results are shown as frequencies
(upper panels), counts (middle panels,
raw data) and counts per g mouse (lower
panel, weight corrected data). For weight
correction, total counts were normalized
to the average mouse weights of female
and male wild type and CERS2-deficient
mice, respectively, (see 4.1.1). Results are
separated for genders as described above
(see 4.1.1). Dots in scatter plots repre-
sent individual mice and black lines rep-
resent means; bar graphs represent means
+ SD (Unpaired t-test; *P<.05, **P<.01,
***P<.001). Data are pooled from indi-
vidual experiments, in which 1 - 2 mice
per genotype were analyzed. The data of
panel A were already published in [1].
Immature Mature
0.0
0.5
1.0
1.5
2.0
2.5
C
el
ls
[x
10
5 /g
 m
ou
se
]
Immature Mature
0
20
40
60
80
100
Fr
eq
ue
nc
y 
[%
]
*
*
Immature Mature
0
1
2
3
4
C
el
ls
 [x
10
6 ]
*
CD4-/CD8+ thymocytes
from female mice
B)
Immature Mature
0
1
2
3
4
C
el
ls
 [x
10
6 ]
Immature Mature
0.0
0.5
1.0
1.5
2.0
2.5
C
el
ls
[x
10
5 /g
 m
ou
se
]
**
Immature Mature
0
20
40
60
80
100
Fr
eq
ue
nc
y 
[%
]
*
*** +/+
gt/gt
CD4-/CD8+ thymocytes
from male mice
A)
49
4 RESULTS
In addition to the quantification of immature and mature SP thymocytes, we determined
the numbers of CD4+ and CD8+ T cells in blood, spleen and lymph nodes of Cers2+/+
and Cers2gt/gt mice, as it was demonstrated by numerous studies that alterations in thymic
egress also affect the size of peripheral T cell populations [78, 89, 91, 93, 97]. Robustly
reduced numbers of CD4+ and CD8+ T cells were found in blood and spleen of Cers2gt/gt
mice, compared to wild type controls (Figure 4.6A and D). Surprisingly, the T cell numbers
in lymph nodes were largely unaffected by ablation of CERS2 (Figure 4.6E and F).
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Figure 4.6: Reduced T cell numbers in blood and spleen of CERS2-deficient mice. (A and B) Numbers of
CD4+ and CD8+ T cells in the blood of wild type (+/+, white dots) and CERS2-deficient mice (gt/gt, black
dots) were determined by flow cytometry. (A) Representative pictures of flow cytometric identification of
CD4+ and CD8+ T cells in the blood. (B) Results are shown as counts per ml blood; (N = 13  14, 5
female and 8  9 male mice per genotype). (C and D) Numbers of CD4+ and CD8+ T cells in the spleen
of wild type and CERS2-deficient mice were determined by flow cytometry. (C) Representative pictures
of flow cytometric identification of splenic CD4+ and CD8+ T cells. (D) Results are shown as counts (left
panel, raw data) and counts per g mouse (right panel, weight corrected data); (N = 16 - 17; 8 female and
8 - 9 male mice per genotype). (E and F) Numbers of CD4+ and CD8+ T cells in the inguinal lymph
nodes of wild type and CERS2 -deficient mice were determined by flow cytometry. (E) Representative
pictures of flow cytometric identification of CD4+ and CD8+ T cells in inguinal lymph nodes. (F) Results
are shown as average counts of both inguinal lymph nodes (left panel, raw data) and average counts from
both inguinal lymph nodes per g mouse (right panel, weight corrected data); (N = 13 - 14; 6 female and
7 - 8 male mice per genotype). (A - F) Numbers in dot plots indicate the percentages of CD4+ and
CD8+ T cells within the parental populations. Dots in scatter plots represent individual mice and black
lines represent means (Unpaired t-test, *P<0.5, **P<.01, ***P<.001). For weight correction, total counts
were normalized to the average mouse weights of female and male wild type and CERS2 -deficient mice,
respectively, (see 4.1.1). Data are pooled from individual experiments, in which 1  3 mice per genotype
were analyzed. Parts of panel B and D (male data) were already published in [1].
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Worthy of note is that except for a reduced percentage of CD4+ T cells within the PBMCs,
the frequencies of CD4+ and CD8+ T cells were not significantly altered in all analyzed
compartments of wild type and Cers2gt/gt mice, indicating that CERS2-deficiency only
affects the cellularity but not the composition of peripheral lymphoid organs (Figure 4.6A,
C, and E).
However, peripheral T cell homeostasis is not only dependend on stable thymic egress,
but also on other processes, such as differentiation, proliferation or apoptosis [184, 204,
205, 206, 207]. Consequently, we investigated if these processes are altered in CERS2 -
deficient mice. First, the frequencies of naive, central memory and effector memory cells
within the CD4+ and CD8+ T cell populations of blood and spleen from Cers2+/+ and
Cers2gt/gt mice were determined by flow cytometry to determine if CERS2-deficiency alters
the differentiation of naive into memory T cells. T cell subsets were discriminated on the
basis of differential surface expression of CD44 and CD62L (naive = CD44low/CD62Lhigh;
central memory = CD44high/CD62Lhigh; effector memory = CD44high/CD62Llow). Except
for a slight but significant shift from more naive to less effector memory CD4 T cells in
CERS2 -deficient mice, no alterations in the frequencies of T cell subsets were observed in
Cers2gt/gt mice compared to Cers2+/+ mice (Figure 4.7).
Second, to examine if CERS2-deficiency increases the levels of cellular stress, which might
e.g. impair (T cell) proliferation [208], the amounts of phosphorylated p38 in protein lysates
of total spleens and of isolated splenocytes from wild type and CERS2 -deficient mice were
determined by immunoblot analysis. P38 is a MAP kinase, which is phosphorylated and
activated by different upstream kinases in response to a diverse range of cellular stressors,
like UV radiation, growth factors or certain ceramides [128, 209]. After activation, p38
can activate various downstream targets to induce repair or protective mechanisms [208].
Cers2gt/gt mice exhibited similar levels of phospho-p38 in total spleens and isolated spleno-
cytes compared to Cers2+/+ mice (Figure 4.8A and B).
Third, to explore if CERS2-deficiency affects the viability of peripheral T cells, the frequen-
cies of living cells within splenic CD4+ and CD8+ T cells from Cers2+/+ and Cers2gt/gt
mice were determined by flow cytometry. Living cells were identified by the absence of An-
nexin 5 on the surface. Comparable frequencies of living cells within the T cell populations
were found in Cers2+/+ and Cers2gt/gt mice (Figure 4.8C and D).
Taken together, the combination of a selective accumulation of egress-competent mature
SP thymocytes in the thymus with a robust peripheral T cell lymphopenia, which is not
caused by alterations in differentiation, proliferation and apoptosis, clearly suggests that
CERS2-deficiency leads to an impaired thymic egress.
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Figure 4.7: CERS2-deficiency has only minor effects on the differentiation of peripheral T cells. Per-
centages of naive, central memory and effector memory cells within CD4+ and CD8+ T cell populations
in the blood and the spleen of wild type (+/+/ white bars) and CERS2-deficient mice (gt/gt, black bars)
were determined by flow cytometry. (A and B) Representative pictures of flow cytometric identification
of naive (CD62L+/CD44-), central memory (CD62L+/CD44+) and effector memory (CD62L-/CD44+)
cells within CD4+ (A) and CD8+ (B) T cell populations from blood. Numbers indicate the percentages
of subpopulations within the parental populations. (C and D) Percentages of naive, central memory and
effector memory cells within CD4+ (C) and CD8+(D) T cell populations from blood (N = 13 - 14; 5 female
and 8 - 9 male mice per genotype). (E and F) Percentages of naive, central memory and effector memory
cells within CD4+ (E) and CD8+(F) T cell populations from spleen (N = 11 - 12; 4 female and 7 - 8 male
mice per genotype). Bar graphs represent means + SD (Unpaired t-test, *P<.05, **<P.01, ***P<.001).
Data are pooled from individual experiments, in which 1 - 3 mice per genotype were analyzed.
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Figure 4.8: No aberrant cellular stress and cell death in splenocytes from CERS2-deficient mice. (A and
B) Levels of phosphorylated and total p38 in lysates of whole spleens (A) and isolated splenocytes (B) of
wild type (+/+) and CERS2-deficient (gt/gt) mice were determined by immunoblot-analysis (N = 4; 2
female (No. 1 - 2) and 2 male (No. 3 - 4) mice per genotype). Data are from a single experiment. (C and
D) Viability of splenic CD4+ and CD8+ T cells from wild type (+/+, white bars) and CERS2-deficient
(gt/gt, black bars) mice was investigated by Annexin 5 surface staining and flow cytometric analysis. (C)
Representative pictures of flow cytometric identification of Annexin 5- CD4+ and CD8+ T cells. Numbers
indicate the percentages of Annexin 5- and Annexin 5+ cells within the parental populations; dashed
curves represent unstained controls and grey-filled curves represent samples. (D) Percentages of Annexin
5- cells within the CD4+ and CD8+ T cell compartments (N = 4 female mice per genotype). Bar graphs
represent means + SD. Data are pooled from individual experiments, in which 1 - 2 mice per genotype
were analyzed.
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4.1.3 CERS2-deficiency distorts the S1P gradient between thymus and blood
The functional S1P gradient that mediates the chemotactic emigration of terminally differ-
entiated thymocytes into the circulation require tightly controlled S1P levels in the thymic
interstitium, in the perivascular space (i. e. at the exit sites) and in the blood. Whereas
the concentration of S1P must be relatively low in the thymic parenchyma, S1P levels
need to be relatively high in the perivascular space and must finally peak in the blood
stream [26, 79, 97]. To investigate if CERS2-deficiency affects the S1P gradient between
thymus and blood, the levels of S1P (and DH-S1P, the phosphorylated form of dihydrosph-
ingosine, which also binds to S1PR1 [210, 211]) in whole thymi, in plasma and in RBCs of
Cers2+/+ and Cers2gt/gt mice were determined by LC/MS/MS. Additionally, the concen-
tration of certain ceramides, sphingomyelins and sphingoid bases were also measured in
order to verify the findings of other studies, which demonstrate that ablation of CERS2 and
the related loss of VLC (very long chain) sphingolipids lead to increased levels of LC (long
chain) sphingolipids, sphingosine and dihydrosphingosine [160, 166, 188]. Mass spectromet-
ric analysis revealed that the levels of S1P and DH-S1P are robustly elevated in all analyzed
compartments of Cers2gt/gt mice compared to Cers2+/+ mice (Figure 4.9A - C). In contrast
to plasma and RBCs, however, the elevation of thymic S1P levels was less pronounced and
did not reach statistical significance. Moreover, CERS2-deficiency resulted in an almost
complete loss of VLC sphingolipids (e.g. C24:1 ceramide or C24:0 sphingomyelin), a com-
pensatory increase in LC sphingolipids (e.g. C16:0 ceramide or C16:0 sphingomyelin) and
an accumulation of sphingoid bases (sphingosine and dihydrosphingosine) in all analyzed
compartments, entirely confirming the results of the above-cited studies.
Although S1P is synthesized in the cytoplasm and has proven intracellular functions, it
must be exported into the extracellular space to form the S1P gradient and to stimulate
(other) cells via their S1P receptors [59, 69, 73]. However, as the results of mass spectro-
metric measurements of whole thymic tissue reflect the combined amounts of intra- and
extracellular S1P, we specifically analyzed if the S1P levels are elevated in the thymic
interstitium of Cers2gt/gt mice (to further investigate the effect of CERS2-deficiency on
the thymic S1P gradient). To this end, surface expression levels of CD69 on the ma-
ture SP thymocytes from Cers2+/+ and Cers2gt/gt mice were reevaluated. CD69 is an
appropriate indicator for the amounts of parenchymal S1P, as it is rapidly internalized
from the plasma membrane upon signaling via the S1P-S1PR1 axis [89]. Compared to cells
from wild type mice, mature CD4+/CD8- and CD4-/CD8+ thymocytes from Cers2gt/gt
mice had substantially reduced surface expression levels of CD69 (Figure 4.10A - C), sug-
gesting that CERS2-deficiency leads to a dramatic increase of the S1P concentration in
thymic parenchyma. S1P-independent causes for the diminished CD69 surface levels were
excluded, as CD69 surface expression on immature SP thymocytes, which are inert to S1P
stimulation, was not affected in Cers2gt/gt mice.
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Figure 4.9: CERS2-deficient mice lack very long chain sphingolipids, but accumulate long chain sph-
ingolipids, sphingoid bases and phosphorylated sphingoid bases in thymus, plasma and RBCs. (A - C)
Amounts of common ceramides (C16:0, C18:0, C20:0, C22:0, C22:6, C24:1 and C24:2), sphingomyelins
(C16:0 and C24:0), spingoid bases (Sph = sphingosine and DH-Sph = dihydrosphingosine) and phospho-
rylated sphingoid bases (S1P = sphingosine-1-phosphate and DH-S1P = dihydrosphingosine-1-phosphate)
in thymus (A, whole organs, shown as pmol/g tissue, N = 4 - 6, 2 - 4 female and 2 male mice per geno-
type), plasma (B, shown as nM, N = 4 - 12, 2 - 7 female and 2 - 5 male mice per genotype) and RBCs
(C, shown as pmol/108RBCs, N = 3 - 9, 3 - 6 female and 0 - 3 male mice per genotype) of wild type
(+/+, white bars) and CERS2-deficient mice (gt/gt, black bars) were measured by mass spectrometry
(n.d. = not determinable = below detection limit). Bar graphs represent means + SD (Unpaired t-test;
*P<.05, **P<.01, ***P<.001). Data are pooled from individual experiments, in which 2 - 4 mice per geno-
type were analyzed. Mass spectrometric analysis was performed by Dr. Markus Gräler (Department of
Anesthesiology and Intensive Care Medicine, Center for Sepsis Control and Care (CSCC), and the Center
for Molecular Biomedicine (CMB), Jena University Hospital, Jena, Germany). Parts of this figure (S1P
measurements) were already published in [1].
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Figure 4.10: CERS2-deficiency leads to reduced surface expression of CD69 on mature SP thymocytes.
CD69 surface expression on immature and mature CD4+/CD8- and CD4-/CD8+ thymocytes from wild
type (+/+, white bars) and CERS2-deficient (gt/gt, black bars) mice was analyzed by flow cytometry.
(A) Representative pictures of flow cytometric analysis of CD69 surface expression on immature and
mature CD4+/CD8- thymocytes. Blue dashed lines indicate the approximate CD69 MFIs of immature
(upper) and mature (lower) CD4+/CD8- thymocytes from the wild type mouse. Red dashed lines indicate
the approximate CD69 MFIs of immature (upper) and mature (lower) CD4+/CD8- thymocytes from the
CERS2-deficient mouse. (B and C) CD69 MFIs (mean fluorescence intensities) of immature and mature
CD4+/CD8- (B) and CD4-/CD8+ (C) thymocytes were normalized to the respective wild type controls,
which were set to 1 (N = 10, 5 male and 5 female mice per genotype). Bar graphs represent means + SD.
Data are pooled from individual experiments, in which 1 - 2 mice per genotype were analyzed. Panels B
and C were already published in [1].
Taken together, Cers2gt/gt mice exhibited substantially elevated levels of S1P in the plasma,
in RBCs and in the thymic interstitium, besides the expected loss of VLC sphingolipids
and the increased concentrations of LC sphingolipids and sphingoid bases. These findings
indicate that ablation of CERS2 dramatically distorts the S1P gradient between thymus
and blood.
4.1.4 Summary
In the first part of this study we investigated via comparative analyses of Cers2+/+ and
Cers2gt/gt mice if the CERS2-dependent regulation of sphingosine levels is important for
the stability of the thymic S1P gradient and thus for efficient emigration of terminally
differentiated thymocytes into the circulation. We found that CERS2-deficiency did not
only lead to an accumulation of sphingosine, but also to robustly elevated levels of S1P,
which strongly distort the S1P gradient at the interface of thymus and blood. Consistently,
thymic egress was impaired in Cers2gt/gt mice, which was indicated by an accumulation of
egress-competent mature SP thymocytes in the thymus and a concomittant peripheral T
cell lymphopenia. Based on these findings, we concluded that the regulation of sphingosine
by CERS2 is an important mechanism to maintain the functional S1P gradient between
thymus and blood and to facilitate efficient thymic egress.
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4.2 S1P-mediated thymic egress is not regulated by CERS2 in thymic
stromal or hematopoietic cells
The S1P gradient that facilitates the emigration of terminally differentiated thymocytes
into the circulation result from low S1P levels in the thymic parenchyma but high S1P
concentrations in the perivascular space and in the blood. Although its exact archi-
tecture is still incompletely understood, it was demonstrated that the thymic S1P gra-
dient depends on many different cell types, including intrathymic hematopoietic cells
(such as DCs or thymocytes), intrathymic non-hematopoietic cells (stroma cells, such
as thymic epithelial cells (TECs), vascular endothelial cells (ECs) or neural crest-derived
pericytes), extrathymic hematopoietic cells (such as erythrocytes or platelets) and ex-
trathymic non-hematopoietic cells (such as vascular endothelial cells (ECs) or hepatocytes)
[97, 92, 89, 91, 78, 98, 212]. Whereas DCs, thymocytes and TECs maintain low S1P levels
in parenchyma via the expression of S1P lyase and LPP3 [89, 91], neural crest-derived
pericytes keep up high S1P levels in the perivascular space, via the synthesis of S1P by
SPHKs [92]. In contrast to these cell types, which exclusively regulate the intrathymic S1P
micromilieu, the main role of erythrocytes, platelets and hepatocytes is to maintain the
extremely high concentration of S1P in the blood [97, 99]. The function of endothelial cells
is rather complex. On the one hand, it is assumed that these cells limit the amounts of
S1P in the perivascular space via the expression of LPP3 to shape the S1P gradient on
the abluminal side of the blood vessels [89]. On the other hand, ECs also contribute to the
maintenance of the high S1P levels in the circulation by secreting considerable of amonts of
S1P into the blood, mediated by SPNS2 [78]. However, whereas the first described function
of endothelial cells is of course restricted to those cells that form blood vessels within the
thymus (intrathymic ECs), the second function is presumably fullfilled by all vascular ECs
of the organism (extrathymic ECs).
In the first part of this study it was discovered that CERS2 is an additional factor that
contributes to the maintenance of the thymic S1P gradient. In the second part, it was
consequently investigated, in which cell types CERS2 is required to exert this function. To
identify possible candidates, flow cytometric analysis was performed to measure CERS2
expression in all of the above-mentioned cell types. For technical reasons, erythrocytes
and platelets were not included in this analysis. Furthermore, hepatocytes were also not
considered, as the high expression of CERS2 in the liver was already proven by other
studies [160, 166]. In return, macrophages were included, although a role of these cells
for S1P-mediated thymic egress has not been documented yet. Flow cytometric analyses
revealed that CERS2 is robustly expressed in all analyzed cell types (Figure 4.11A - D). This
broad expression did not lead to the identification of possible candidates, in which CERS2
might be essential for the maintenance of thymic S1P gradients, but rather suggested that
CERS2 could exert this function in any of the tested cell types. However, as investigations
on the individual role of CERS2 in all of these cell types were beyond the scope of this study,
it was decided to investigate alternatively if CERS2 is generally required in hematopoietic
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or thymic stromal cells to maintain the chemoattractive S1P gradient between thymus and
blood. To this end, bone marrow reconstitution and thymus transplantation experiments
were performed.
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Figure 4.11: CERS2 is expressed in all major hematopoietic and non-hematopoietic cell types of the thy-
mus. CERS2 expression in thymocytes, dendritic cells (DCs), macrophages (MΦs), thymic epithelial cells
(TECs), vascular endothelial cells (ECs) and mesenchymal cells (MECs) was determined by intracellular
staining and subsequent flow cytometric analysis. Before thymic stromal cells were stained against CERS2,
they were pre-enriched by depletion of hematopoietic cells via MACS using CD45-microbeads (see 3.2.4.4,
3.2.4.7 and 3.2.4.10. (A) Gating strategy for flow cytometric identification of thymocytes (CD11c-/F4/80-),
thymic dendritic cells (DCs, CD11c+/F4/80-) and macrophages (MΦs, CD11cintermediate/F4/80+), accord-
ing to [213]. (B) Gating strategy for flow cytometric discrimination between thymic epithelial cells (TECs,
CD45-/EpCam+), vascular endothelial cells (ECs, CD45-/EpCam-/CD31+) and neural crest-derived mes-
enchymal cells (MECs, CD45-/EpCam-/CD31-); with minor modifications according to [214]. (C) Repre-
sentative pictures of flow cytometric quantification of CERS2 expression in all analyzed cell types. Cells
from wild type mice (+/+, continuous lines) were used to investigate CERS2 expression. Cells from
CERS2-deficient mice (gt/gt, black, filled curves) were used as specificity control for the CERS2 staining.
Unstained cells (dashed lines) were used as negative control for the CERS2 staining. (D) CERS2 expression
in all analyzed cell types. Results are shown as MFIs (mean fluorescence intensities); (N = 3 male wild
type mice for quantification and 1 CERS2-deficient mouse as specificity control). Bar graphs represent
means + SD. Data are from a single experiment. This figure was taken from [1] and modified.
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4.2.1 CERS2 in hematopoietic cells is dispensable for S1P-mediated thymic
egress
Bone marrow reconstitution allows the complete replacement of the hematopoietic system
of recipient mice with that of donor mice. Initially, recipients are myeloablated by a lethal
irradiation via a gamma ray source. Shortly thereafter, freshly isolated bone marrow cells
from donor mice are transplanted into the irradiated recipients. Within a few weeks, donor
HSCs (hematopoietic stem cells) populate the empty niches in the bone marrow and start
to reconstitute the whole hematopoietic system. Mice, whose hematopoietic system has
been replaced via bone marrow reconstitution, are termed bone marrow chimeras, as their
hematopoietic cells have a another genetic origin than the rest of their cells. It is commom
practice to use recipient and donor mice from strains, which carry different alleles of pan
leukocyte surface markers, such as CD45 (CD45.1/CD45.2) or CD90 (CD90.1/CD90.2),
respectively. Thus, remaining host cells and donor-derived cells are distinguishable, e.g.
by flow cytometry, and the success of engraftment can be easily monitored ([215, 216] and
3.1.10).
In the present study, bone marrow reconstitution experiments were performed to examine if
CERS2 is required in hematopoietic cells to maintain the chemoattractive S1P gradient be-
tween thymus and blood. For this purpose, irradiated wild type recipients (CD45.1+) were
reconstituted with bone marrow from either Cers2gt/gt or Cers2+/+ mice (both CD45.2+),
to generate chimeras with a CERS2 -deficient hematopoietic system (gt/gt  +/+) and
control chimeras with a wild type hematopoietic system (+/+  +/+). Ten weeks post
reconstitution, replacement of the hematopoietic system was verified and S1P-mediated
thymic egress was analyzed.
To control the reconstitution of the hematopoietic system by donor bone marrow, the fre-
quencies of host- (CD45.1+) and donor-derived cells (CD45.2+) within total bone marrow
cells, total thymocytes and total splenocytes of wild type and CERS2 -deficient chimeras
were determined by flow cytometry (Figure 4.12A - D). In all analyzed compartments, more
than 80% of the cells were found to be CD45.2+, clearly demonstrating a successful engraft-
ment of the donor cells. The genotypes of the reconstituted hematopoietic cells were recon-
firmed on a functional level by demonstrating via mass spectrometry that donor-derived
thymocytes from Cers2gt/gt chimeras lack C24:0 ceramides and accumulate C16:0 ceramides
in comparison to donor-derived thymocytes from Cers2+/+ chimeras (Figure 4.12E). Al-
though the analysis of wild type and Cers2gt/gt mice revealed that also sphingomyelins are
affected by ablation of CERS2 (see 4.1.3), no alteration in the levels of C16:0 or C24:0 sphin-
gomyelins were detected between donor-derived thymocytes from Cers2+/+ and Cers2gt/gt
chimeras, suggesting that the wild type environment of the recipients might be able to
counterbalance the aberrant turnover of complex sphingolipids in CERS2 -deficient thymo-
cytes.
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Figure 4.12: Successful engraftment of wild type and CERS2 -deficient bone marrow into lethally ir-
radiated wild type mice. Bone marrow chimeras were generated by reconstitution of lethally irradiated
female wild type mice (CD45.1+) with bone marrow from female wild type (+/+  +/+, light red bars)
or CERS2-deficient (gt/gt  +/+, dark red bars) mice (both CD45.2+). 10 weeks post reconstitution,
recipient mice were analyzed for successful engraftment of donor bone marrow. (A - D) Frequencies of host
(CD45.1+) and donor-derived (CD45.2+) cells were determined by flow cytometry. Representative pictures
of flow cytometric identification of host and donor-derived cells within bone marrow cells (A), thymocytes
(B) and splenocytes (C). Numbers indicate the percentages of host and donor cells within parental pop-
ulations. (D) Percentages of donor-derived cells (CD45.2+) within bone marrow cells, thymocytes and
splenocytes (N = 6 chimeras per donor genotype). (E) Donor-derived thymocytes (CD45.2+) from wild
type (+/+ -> +/+) and CERS2-deficient (gt/gt -> +/+) chimeras were negatively isolated by MACS (=
depletion of CD45.1+ thymocytes) and analyzed for the amounts of ceramide (16:0 and 24:0) and sphin-
gomyelin (16:0 and 24:0) species by mass spectrometry (N = 5 - 6 chimeras per donor genotype). Results
were normalized to the respective cholesterol contents and shown as pmol of ceramide or sphingomyelin per
100 pmol cholesterol. Bar graphs represent means + SD (n.d. = not determinabe = below detection limit).
Data are pooled from 2 - 4 independent experiments, in which 1 - 2 recipients were reconstituted with
bone marrow from 1 donor mouse per genotype, respectively. Generation of bone marrow chimeras was
performed in cooperation with the group of Dr. Christian Kurts (Institute for Experimental Immunology,
University Hospital Bonn, Germany). Mass spectrometric analysis was performed by Dr. Markus Gräler
(Department of Anesthesiology and Intensive Care Medicine, Center for Sepsis Control and Care (CSCC),
and the Center for Molecular Biomedicine (CMB), Jena University Hospital, Jena, Germany). The data
of panel B and parts of the data of panel D (thymocyte data) were already published in [1].
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After confirming the successful reconstitution, the same key parameters of efficient S1P-
mediated thymic egress that have been analyzed in the initial characterization of wild type
and CERS2 -deficient mice (see 4.1.2 and 4.1.3) were examined in Cers2+/+ and Cers2gt/gt
chimeras. Wild type and CERS2 -deficient chimeras had equal concentrations of S1P in
the plasma, similar frequencies and numbers of mature SP thymocytes in the thymus
and comparable counts of T cells in blood and spleen (Figure 4.13A - E), collectively
indicating that the functional S1P gradient is presumably not dependent on CERS2 in the
hematopoietic compartment.
Worthy of note is that the mature SP thymocytes in Cers2gt/gt chimeras had a decreased
surface expression of CD69 compared to Cers2+/+ chimeras, which indicates an excessive
stimulation via the S1P-S1PR1 axis (Figure 4.13D and E). Consequently, it was assumed
that CERS2-deficiency in hematopoietic cells might alter the S1P microenvironment in
the thymus without disrupting the S1P gradient and the corresponding emigration of
terminally differentiated thymocytes into the periphery.
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Figure 4.13: Deficiency of CERS2 in hematopoietic cells has no effect on thymic egress. (A) Concen-
tration of plasma S1P from wild type and CERS2 -deficient chimeras was measured by mass spectrometry
(N = 6  7 chimeras per genotype). (B and C) Percentages (left) and counts (right) of donor-derived
(CD45.2+) immature (CD62Llow/CD69high) and mature (CD62Lhigh/CD69intermediate) CD4+/CD8- (B)
and CD4-/CD8+ (C) thymocytes from wild type (+/+  +/+, light red bars and dots) and CERS2 -
deficient chimeras (gt/gt  +/+, dark red bars and dots) were determined by flow cytometry (N = 4
chimeras per genotype). (D and E) Flow cytometric analysis of CD69 surface expression on immature and
mature CD4+/CD8- (D) and CD4-/CD8+ (E) thymocytes from wild type and CERS2 -deficient chimeras.
Results are shown as CD69 MFIs. Data were normalized to wild type chimeras, which were set to 1 (N =
4 chimeras per genotype). (F) Total counts of donor-derived CD4+ and CD8+T cells per ml blood from
wild type and CERS2 -deficient chimeras were determined by flow cytometry (N = 4 chimeras). (G) Total
counts of donor-derived CD4+ and CD8+ T cells in the spleens of wild type and CERS2 -deficient chimeras
were determined by flow cytometry (N = 6 chimeras per genotype). Dots in scatter plots represent indi-
vidual chimeras and black lines represent means; bar graphs represent means + SD. Data are pooled from
2 - 4 independent experiments, in which 1 - 2 recipients were reconstituted with bone marrow from 1 donor
mouse per genotype, respectively. Generation of bone marrow chimeras was performed in cooperation with
the group of Dr. Christian Kurts (Institute for Experimental Immunology, University Hospital Bonn, Ger-
many). Mass spectrometric analysis was performed by Dr. Markus Gräler (Department of Anesthesiology
and Intensive Care Medicine, Center for Sepsis Control and Care (CSCC), and the Center for Molecular
Biomedicine (CMB), Jena University Hospital, Jena, Germany). The data of panels A - E were already
published in [1].
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4.2.2 CERS2 in thymic stromal cells is dispensable for S1P-mediated thymic
egress
In a thymus transplantation, thymi from fetal or neonatal donor mice are grafted under the
kidney capsule of recipient mice. Within 3 - 4 weeks, the thymocytes (and other hematopoi-
etic cells) from the donor are replaced by cells from the host, while the donor stroma re-
mains unaltered [217]. At the end of this process, thymic grafts consist of hematopoietic
cells from the host and of stroma cells from the donor, allowing the subsequent analysis
of stroma-specific functions. As described for the generation of bone marrow chimeras (see
4.2.1), the donor and recipient mice that are used for thymus transplantation studies are
often derived from strains, which differentially express CD45.1 and CD45.2 or CD90.1 and
CD90.2. Thus, the exchange of the donor cells by hematopoietic cells from the host can
be easily controlled by flow cytometry.
In this study, thymus transplantation experiments were performed to examine if CERS2
is required in thymic stromal cells to maintain the chemoattractive S1P gradient between
thymus and blood. To this end, thymus lobes from neonatal Cers2+/+ and Cers2gt/gt
mice (both CD45.2+) were co-transplanted under the kidney capsule of wild type recipients
(CD45.1+) (Figure 4.14A). The presence of a wild type (+/+  +/+) and a CERS2 -
deficient thymic graft (gt/gt  +/+) in the same recipient ensured a high degree of
comparability, as both lobes were populated with wild type TSPs (thymic seeding pro-
genitor) from the same origin. Four to five weeks post transplantation, the exchange of
the hematopoietic cells in the grafts was verified and S1P-mediated emigration of mature
SP thymocytes into the periphery was analyzed.
To verify the replacement of hematopoietic cells from the donor by cells from the recipient,
the frequencies of host- (CD45.1+) and donor-derived cells (CD45.2+) within total thymo-
cytes in wild type and CERS2 -deficient thymic grafts were determined by flow cytome-
try (Figure 4.14B and C). Close to 100% of all thymocytes in both thymic grafts were
found to be CD45.1+, indicating that cells from the host have completely displaced the
hematopoietic cells from the donor.
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Figure 4.14: Successful transplantation of wild type and CERS2 -deficient thymus lobes under the kid-
ney capsule of wild type recipients. Lobes of wild type (+/+) and CERS2 -deficient (gt/gt) thymi from
neonatal mice (both CD45.2+) were transplanted under the kidney capsule of male wild type recipients
(CD45.1+). 4-5 weeks after the transplantation, engraftment of donor lobes and successful replacement of
donor thymocytes by cells from the host was investigated by flow cytometry. (A) Representative photo of
renal grafts from wild type and CERS2 -deficient mice 4 weeks after transplantation. The original image
background was replaced with a grey area to increase contrast. (B and C) Percentages of host- (CD45.1+)
and donor-derived (CD45.2+) cells in wild type (+/+ +/+, light blue bars) and CERS2 -deficient thymic
grafts (gt/gt  +/+, dark blue bars) were determined by flow cytometry. (B) Representative pictures
of flow cytometric identification of host- and donor-derived cells within the thymocyte fraction. Numbers
indicate the percentages of host and donor cells within the parental populations. (C) Percentages of host
cells (CD45.1+) within the thymocyte fraction (N = 8 lobes per donor genotype). Data are pooled from
4 independent experiments, in which the two thymic lobes of a wild type and a CERS2 -deficient mouse
were separated and transplanted into two wild type recipients (one wild type and one Cers2gt/gt lobe per
recipient), respectively. Bar graphs represent means + SD. Thymus transplantation experiments were
performed in cooperation with the group of Dr. Christian Kurts (Institute for Experimental Immunology,
University Hospital Bonn, Germany). The data of panels B and C were already published in [1].
It was observed that wild type and CERS2 -deficient thymic grafts harbored the same
quantities of mature SP thymocytes (Figure 4.15A and B). Likewise, the surface levels
of CD69 on mature SP thymocytes were comparable between both grafts (Figure 4.15C
and D). These findings indicate that the functional S1P gradient is presumably also not
dependent on CERS2 in the thymic stromal compartment. Unfortunately, it was not
feasible to verify this hypothesis by analyzing other key parameters of efficient thymic
egress, such as the numbers of CD4+ and CD8+ T cells in blood and spleen, as all peripheral
T cells in the recipients carry host signature and it is therefore impossible to determine
from which thymus they entered the periphery (endogenous thymus, wild type thymus
graft, CERS2 -deficient thymus graft).
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Figure 4.15: Deficiency of CERS2
in thymic stromal cells has no ef-
fect on thymic egress. (A and B)
Frequencies (left) and counts per
lobe (right) of host (CD45.1+) im-
mature (CD62Llow/CD69high) and
mature (CD62Lhigh/CD69intermediate)
CD4+/CD8- (A) and CD4-/CD8+ (B)
thymocytes in wild type (+/+ → +/+,
light blue bars and dots) and CERS2-
deficient thymic grafts (gt/gt → +/+,
dark blue bars and dots) were determined
by flow cytometry (N = 8 lobes per
genotype). (C and D) Flow cytometric
analysis of CD69 surface expression on
immature and mature CD4+/CD8- (C)
and CD4-/CD8+ (D) thymocytes from
wild type and CERS2-deficient thymic
grafts. Results are shown as CD69 MFIs.
Data were normalized to wild type grafts,
which were set to 1 (N = 8 lobes per
genotype). Dots in scatter plots represent
individual lobes and black lines represent
means; bar graphs represent means +
SD. Data are pooled from 4 independent
experiments, in which the two thymic
lobes of a wild type and a CERS2-deficient
mouse were separated and transplanted
into 2 wild type recipients (1 wild type
and 1 CERS2-deficient lobe per recipient),
respectively. Thymus transplantation ex-
periments were performed in cooperation
with the group of Dr. Christian Kurts
(Institute for Experimental Immunology,
University Hospital Bonn, Germany). The
data of this figure were already published
in [1].
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4.2.3 Summary
In the second part of the present study, it was investigated if CERS2 is required in
hematopoietic or thymic stromal cells to maintain the chemoattractive S1P gradient be-
tween thymus and blood. To address this issue, it was analyzed if mice, which lack CERS2
specifically in the hematopoietic or in the thymic stromal compartment, exhibit the same
impairments in thymic emigration as Cers2gt/gt mice. Surprisingly, CERS2-deficiency in
neither of both compartments affected S1P-mediated emigration of mature SP thymocytes
into the circulation, clearly indicating that the thymic S1P gradient is independent of
CERS2 in hematopoietic or thymic stromal cells. As discussed later, it was consequently
assumed that the thymic S1P gradient requires CERS2 in non-hematopoietic extrathymic
cell types, such as hepatocytes or vascular endothelial cells, as these are the only known
regulators of the thymic S1P gradient, which were not covered by the bone marrow recon-
stitution and thymus transplantation experiments.
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4.3 S1P-mediated thymic egress is independent of CERS4
The first two parts of this study suggest that the CERS2-dependent regulation of sphingo-
sine is essential for the maintenance of the chemoattractive S1P gradient at the interface
of thymus and blood. Apart from CERS2, however, the family of ceramide synthases com-
prises five other members (CERS1, CERS3 - 6), which also use sphingosine as substrate for
the synthesis of different ceramides species. In the third part of this study, it was there-
fore investigated if the regulation of S1P-mediated thymic egress is an exclusive feature of
CERS2 or if other ceramide synthases also contribute to the stabilization of the thymic
S1P gradient.
To adress this issue, S1P-mediated thymic egress was comparatively investigated in wild
type (Cers4+/+) and CERS4 -deficient mice (Cers4Δneo/Δneo, see 3.1.10). CERS4 appeared
to be the most promising candidate for having a similar function as CERS2, since it is
the second most abundant ceramide synthase family member, with a robust expression
in many of the tissues and organs that are known to be relevant for the maintenance of
the thymic S1P gradient, such as the liver or the thymus [155]. In contrast to that, the
other ceramide synthases are either weakly expressed (CERS5 and CERS6) or restricted
to particular organs, e.g. to the brain (CERS1) or to the testes (CERS3) [155].
Levels of S1P in thymus and plasma, frequencies and numbers of mature SP thymocytes
in the thymus and numbers of CD4+ and CD8+ T cells in blood and in spleen were
comparable in wild type and CERS4 -deficient mice (Figure 4.16A - D, G and H). Likewise,
also the surface expression of CD69 on mature SP thymocytes was unaffected by ablation
of CERS4 (Figure 4.16E and F). These findings consistently indicate that S1P-mediated
thymic egress is independent of CERS4. Consequently, it was assumed that the regulation
of the thymic S1P gradient is not a general function of all ceramide synthases, but is most
likely specific for CERS2. However, a contribution of CERS1, CERS3, CERS5 and CERS6
to the stabilization of the gradient can not be excluded.
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Figure 4.16: Deficiency of CERS4 has no effect on thymic egress. (A) Concentration of plasma S1P from
wild type and CERS4 -deficient mice was measured by mass spectrometry (N = 5 male mice per genotype).
(B) Mass spectrometric measurement of S1P levels in thymi (whole organ) of wild type and CERS4 -
deficient mice, shown as pmol per g tissue (N = 5  7 male mice per genotype. (C and D) Frequencies
(left) and counts (right) of immature (CD62Llow/CD69high) and mature (CD62Lhigh/CD69intermediate)
CD4+/CD8- (C) and CD4-/CD8+ (D) thymocytes from wild type (+/+, light green bars and dots) and
CERS4 -deficient mice (Δ/Δ, dark green bars and dots) were determined by flow cytometry (N = 5 male
mice per genotype). (E and F) Flow cytometric analysis of CD69 surface expression on immature and
mature CD4+/CD8- (E) and CD4-/CD8+ (F) thymocytes from wild type and CERS4 -deficient mice.
Results are shown as CD69 MFIs. Data were normalized to wild type mice, which were set to 1 (N = 5
male mice per genotype). (G) Total counts of CD4+ and CD8+T cells per ml blood from wild type and
CERS4 -deficient mice were determined by flow cytometry (N = 4 male mice per genotype). (H) Total
counts of CD4+ and CD8+ T cells in the spleens of wild type and CERS4 -deficient mice were determined by
flow cytometry (N = 6 male mice per genotype). Dots in scatter plots represent individual mice and black
lines represent means; bar graphs represent means + SD. Data are pooled from individual experiments, in
which 1 - 2 mice per genotype were analyzed. Mass spectrometric analysis was performed by Dr. Markus
Gräler (Department of Anesthesiology and Intensive Care Medicine, Center for Sepsis Control and Care
(CSCC), and the Center for Molecular Biomedicine (CMB), Jena University Hospital, Jena, Germany).
The data of this figure were already published in [1].
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4.4 Excursus: Early T cell development in female mice depends on
CERS2
In previous analyses, it was discovered that CERS2-deficiency leads to a selective reduction
of the total thymocyte numbers in female mice (see 4.1.1), demonstrating that CERS2 has
a gender-specific function for T cell development, in addition to its role as regulator of
efficient S1P-mediated thymic egress.
Interestingly, it was shown by flow cytometry that ablation of CERS2 in female mice leads
to a significant reduction in the frequencies and numbers of DN1 thymocytes, which repre-
sent the initial precursor population, from which all other thymocytes derive (Figure 4.17A
and B). Consequently, it was assumed that the thymic atrophy in female CERS2 -deficient
mice is caused by impairments in the earliest stages of T cell development. Consistent with
this hypothesis, female Cers2gt/gt mice exhibited decreased thymocyte counts throughout
all developmental stages that follow the DN1 phase (DN2 to SP). Worthy of note is that
the reduction in the numbers of DN3, DN4 and CD8SP thymocytes was comparably weak
and did not reach statistical significance. Surprisingly, CERS2-deficiency also led to dimin-
ished frequencies of DN1 thymocytes in male mice. Compared to female mice, however,
this reduction was smaller and not accompanied by decreased thymocyte numbers in any
developmental stage (Figure 4.17C). These findings indicate that ablation of CERS2 selec-
tively affects early T cell development in female mice.
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Figure 4.17: Reduced numbers of DN1 and DN2 thymocytes in the thymi of female CERS2 -deficient
mice. Percentages and counts of DN thymocyte subpopulations in the thymi of wild type (+/+, white
bars and dots) and CERS2 -deficient (gt/gt, black bars and dots) mice were determined by flow cytome-
try. (A) Representative pictures of flow cytometric identification of DN thymocyte subpopulations (DN1
(CD44+/CD25-), DN2 (CD44+/CD25+), DN3 (CD44-/CD25+) and DN4 (CD44-/CD25-)). Numbers in-
dicate the percentages of subpopulations within the parental populations. (B) Percentages (upper panel),
counts (middle panel, raw data) and counts per g mouse (lower panel, weight corrected data) of DN thy-
mocyte subpopulations in the thymi of female mice (N = 12 mice per genotype). (C) Percentages (upper
panel), counts (middle panel, raw data) and counts per g mouse (lower panel, weight corrected data) of
DN thymocyte subpopulations in the thymi of male mice (N = 8  9 mice per genotype). For weight
correction, total counts were normalized to the average mouse weights of female and male wild type and
CERS2 -deficient mice, respectively, (4.1.1). Dots in scatter plots represent individual mice and black lines
represent means; bar graphs represent means + SD (Unpaired t-test; *P<.05, **P<.01, ***P<.001). Data
are pooled from individual experiments, in which 1  2 mice per genotype were analyzed.
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At several stages of thymic development, thymocyte populations are shaped by apop-
tosis and proliferation. To examine if alterations in these processes contribute to the
reduced thymic cellularity in female CERS2 -deficient mice, the frequencies of Annexin
5- and Ki67+ cells within the DN, the DP and the SP thymocyte populations of female
Cers2+/+ and Cers2gt/gt mice were determined by flow cytometry. Whereas Annexin 5
labels apoptotic/necrotic cells and serves thus as viability marker, the expression of Ki67
identifies non G0 cells and serves thus as marker for proliferation. CERS2-deficiency did not
affect the percentages of Annexin 5- and Ki67+ cells in the analyzed thymocyte subpopula-
tions, suggesting that the thymic atrophy in female CERS2 -deficient mice is predominantly
caused by the developmental defects in the DN1 stage and not by aberrant apoptosis or
proliferation (Figure 4.18 and 4.19).
Taken together, these findings indicate that CERS2 supports T cell development in female
thymi by regulating the earliest steps of thymocyte differentiation.
Figure 4.18: Deficiency of CERS2
has no impact on the percentage of vi-
able cells in female thymi. Viabil-
ity of major thymocyte subpopulations
from female wild type (+/+, with bars)
and CERS2-deficient (gt/gt, black bars)
mice was investigated by Annexin 5 sur-
face staining and flow cytometric analy-
sis. (A) Representative pictures of flow
cytometric identification of Annexin 5-
DN (CD4-/CD8-), DP (CD4+/CD8+),
CD4+/CD8- and CD4-/CD8+thymocytes.
Numbers indicate the percentages of An-
nexin 5- and Annexin 5+ cells within the
parental populations; dashed curves rep-
resent unstained controls and grey curves
represent samples. (B) Percentages of
Annexin 5- cells within the DN, DP,
CD4+/CD8- and CD4-/CD8+ compart-
ments (N = 4 female mice per genotype).
Bar graphs represent means + SD. Data
are pooled from individual experiments, in
which 1 - 2 mice per genotype were ana-
lyzed.
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Figure 4.19: Deficiency of CERS2 has
no impact on the percentage of proliferat-
ing cells in female thymi. The frequen-
cies of proliferating cells within the ma-
jor thymocyte subpopulations from female
wild type (+/+, with bars) and CERS2-
deficient (gt/gt, black bars) mice was in-
vestigated by an intracellular Ki67 stain-
ing and flow cytometric analysis. (A)
Representative pictures of flow cytometric
identification of Ki67+ DN (CD4-/CD8-),
DP (CD4+/CD8+), CD4+/CD8- and
CD4-/CD8+thymocytes. Numbers indi-
cate the percentages of Ki67+ cells within
the parental populations. (B) Percent-
ages of Ki67+ cells within the DN, DP,
CD4+/CD8- and CD4-/CD8+ compart-
ments (N = 4 female mice per genotype).
Bar graphs represent means + SD. Data
are pooled from individual experiments, in
which 1 - 2 mice per genotype were ana-
lyzed.
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5 Discussion
The process of thymic egress is of fundamental importance for the adaptive immune sys-
tem and thus for the protection against various invading pathogens, as it constantly re-
plenishes the peripheral TCR repertoire with new specificities [19, 26]. The main driver
of thymic emigration is a chemoattractive gradient of the lipid mediator S1P, which ex-
tends from the thymic parenchyma into the blood stream [99]. While passing negative
selection, SP thymocytes develop from an egress-incompetent (immature) into an egress-
competent (mature) state, as they induce surface expression of S1PR1, which enables them
to sense the directional information of the S1P gradient and to exit chemotactically into
the circulation [26, 89]. Despite its importance, the exact architecture of the thymic S1P
gradient, as well as the regulatory mechanisms that maintain the functional differences in
S1P concentration are still insufficiently understood [79].
In this study, we hypothesized that CERS2, as regulator of the S1P precursor sphingosine,
might be important for S1P production and thus for the maintenance of the chemoattrac-
tive S1P gradient between thymus and blood. To verify this hypothesis we comparatively
analyzed the shape of the thymic S1P gradient and the efficiency of thymic egress in wild
type and CERS2 -deficient mice. We observed that ablation of CERS2 did not only lead to
the expected severe alterations in the turnover of sphingosine, but also to a distortion of
the S1P gradient and a consistent impairment of the emigration of terminally differentiated
thymocytes into the circulation. However, by performing bone marrow reconstitution and
thymus transplantation experiments, we found that these phenotypes are neither due to
the deficiency of CERS2 in hematopoietic cells nor caused by the absence of CERS2 in
thymic stromal cells. Based on these findings, we concluded that CERS2 is required in non-
hematopoietic extrathymic cells to maintain the functional S1P gradient between thymus
and blood and to facilitate efficient thymic egress of terminally differentiated thymocytes
into the circulation.
5.1 CERS2 in vascular endothelial cells maintains the thymic S1P gra-
dient and faciliates efficient thymic egress by limiting the levels of
S1P in the blood
Although their exact architecture has still not been resolved, it is assumed that the S1P gra-
dient between thymus and circulation results from low S1P levels in the whole parenchyma
but high S1P levels in the perivascular space (where the mature SP thymocytes cross the
endothelium and enter the circulation) and in the blood [26, 78, 79]. According to the
current understanding, these functional differences in S1P concentration are the result of
local imbalances in S1P production, export and degradation. Whereas the low parenchymal
S1P concentration is maintained by TECs and DCs, which degrade S1P via LPP3 or S1P
lyase, it was demonstrated that neural crest-derived pericytes foster the high S1P levels
at the exit sites by SPHK-dependent S1P production and subsequent export [89, 91, 92].
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The high S1P amounts in the blood, which are even higher than those in the perivascu-
lar space, most likely result from several mechanism. First, multiple cell types (vascular
endothelial cells, hepatocytes, erythrocytes and platelets) contribute to the production, se-
cretion and stabilization of S1P in the plasma [78, 98, 99, 212]. Second, circulatory S1P is
bound to carriers proteins (albumin or HDL), which presumably increase its stability [218].
Third, erythrocytes, which represent the major blood cell population, lack expression of
S1P lyase, SPPs and LPPs. Consequently, blood has low S1P degrading capacities [99].
Although the importance of high S1P levels in the blood for efficient thymic egress has
been demonstrated in several studies, the underlying mechanisms remain elusive [78, 79].
We observed that CERS2-deficiency distorts the thymic S1P gradient, indicated by ele-
vated S1P levels in the thymic parenchyma and in the blood (Figure 4.9 and 4.10). Con-
comittantly, mature SP thymocytes accumlated in the thymus of Cers2gt/gt mice, while the
periphery exhibited a significant T cell lymphopenia, which suggests a considerable impair-
ment in thymic egress (Figure 4.4, 4.5 and 4.6). It was demonstrated in several publications
that even small alterations in S1P levels of thymus or blood can readily compromise the
functionality of the S1P gradient and thus impair efficient emigration of newly formed T
cells into the circulation. Interestingly, this holds true for lowering and for elevating the
S1P concentration in any of the relevant compartments [78, 92, 89, 91]. It could, for in-
stance, be shown that deficiency of SPHKs in neural crest-derived pericytes, which leads
to decreased S1P levels at the exit sites, or ablation of SPNS2 in vascular endothelial cells,
which causes a reduction of the S1P concentration in the blood, weakens the attraction of
the gradient and thus interferes with thymic egress [78, 92]. Likewise, it was demonstrated
that deletion of LPP3 in TECs or ablation of S1P lyase in DCs, which results in a robust
elevation in the interstitial S1P concentration, also impairs efficient exit into the periphery.
In this situation, however, the elevated S1P levels lead to an internalization of S1PR1 from
the cell surface, which desensitizes the newly formed T cells before they have entered the
circulation and thus causes their sequestration in the thymus [89, 91]. In the light of these
findings, it is most likely that the increased concentration of S1P in the thymic interstitium
of CERS2 -deficient mice might also exceed the threshold of desensitization and thus lead
to a slowed egress of the mature SP thymocytes into the periphery. Measuring the surface
expression of S1PR1 on mature SP thymocytes from CERS2-deficient and wild type mice,
would be a straightforward way to substantiate this hypothesis. Although several publi-
cations describe flow cytometric assays to detect surface S1PR1, we were not successful
in establishing these protocols in our laboratory. Therefore, the comparative analysis of
S1PR1 surface expression on mature SP thymocytes from Cers2+/+ and Cers2gt/gt mice
remains a future endeavour. Nonetheless, our findings collectively indicate that CERS2 is
important for the S1P gradient and efficient thymic egress, as it contributes to the limita-
tion of S1P levels in thymus and blood. Thus, CERS2 has a similar, but not redundant
function as the S1P degrading enzymes LPP3 or S1P lyase.
Although CERS2 is ubiquitously expressed in thymic cells, we surprisingly found that
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the exclusive ablation of CERS2 in all hematopoietic or all thymic stromal cells did not
phenocopy the impaired thymic egress that was observed in Cers2gt/gt mice (Figure 4.13
and 4.15). Therefore, we concluded that CERS2 is mainly required in non-hematopoietic
extrathymic cell types to facilitate S1P-mediated thymic emigration. As these cell types
predominantly influence the concentration of S1P in the blood [78, 98], it must be assumed
that CERS2 maintains the functional thymic S1P gradient and efficient egress exclusively
via limiting the levels of circulatory S1P. The need for high and stable S1P levels in
the blood was initially described by Pappu et al., who demonstrated that circulatory S1P
(alone) is able to promote the emigration of mature SP thymocytes into the circulation [97].
In the corresponding study, mice were generated, which lack both SPHKs in many different
tissues (such as the hematopoietic system, vascular endithelium, lymphatic endothelium,
the liver and additional organs), resulting in reduced S1P levels in the blood and in all
lymphoid organs. Consequently, thymic egress was abrogated. However, exclusive reconsti-
tution of plasma S1P, via the transfusion of wild type erythrocytes, restored thymic egress
to more than 50%, compared to wild type mice. Despite these findings, it remains elusive
how circulatory S1P can affect the intrathymic microenvironment and stimulate mature
SP thymocytes, although the endothelium is a diffusion barrier. One potential explana-
tion bases upon investigations of Bode and Sensken et al., who demonstrated that S1P
from the blood can principally access lymphoid organs via transcellular transport through
endothelial cells [219, 220]. Thus, the high amount of S1P in the circulation could directly
shape the gradient on the abluminal side of the blood vessel. Another theory favors a
model, in which the high levels of circulatory S1P do not only affect the thymocytes di-
rectly, but contribute to thymic egress by regulating the permeabilty of the endothelium.
This hypothesis was developed, as it was shown in different studies that S1P signaling is
important for vascular integrity [26, 79, 221].
Assuming that CERS2 regulates thymic egress mainly via limiting the amounts of cir-
culatory S1P, the increased concentration of S1P in the thymic interstitium of Cers2gt/gt
mice, which eventually leads to the desensitization and the subsequent sequestration of ma-
ture SP thymocytes, are presumably not due to intrathymic alterations in S1P turnover,
but must be caused predominantly by the elevated levels of S1P in the blood. Perhaps,
large quantities of the accumulated S1P in the circulation are indeed transported into
the thymus via the transcytosis mechanism that was proposed by Bode and Sensken et
al. [219, 220]. It should be noted that mice with an exclusive ablation of CERS2 in the
hematopoietic system also exhibited signs of elevated S1P amounts in the thymic intersti-
tium (Figure 4.13D and E). Although these alterations were obviously not potent enough
to impair thymic egress on their own, they might aggravate the blood-dependent block
in thymic egress in the Cers2gt/gt mice. As mentioned above, circulatory S1P is also im-
portant for the maintenance of vascular integrity. Consequently, it is conceivable that the
increased levels of S1P in the circulation of Cers2gt/gt mice impair thymic egress not only
by raising the intrathymic S1P concentration, but also by altering the permeability of the
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vascular endothelium.
Until now, the only identified non-hematopoietic regulators of blood S1P are vascular en-
dothelial cells and hepatocytes. Whereas vascular endothelial cells directly secrete S1P into
the plasma, hepatocytes contribute to the stabilization of circulatory S1P via the produc-
tion of apoM, which is the carrier of S1P in HDL [78, 98]. Both cell types robustly express
CERS2 (Figure 4.11 and [155]). However, it was demonstrated in a study of Pewzner-Jung
et al. that CERS2-deficiency had no effect on the S1P levels in the liver [161]. Moreover,
Liu et al. showed that chemical inhibition of ceramide synthases in primary hepatocytes
had no effect on the intracellular levels and on the secretion of S1P in vitro [212]. Therefore,
we finally concluded that CERS2 must be required in vascular endothelial cells to limit
the levels of circulatory S1P and to maintain thus the S1P gradient in the thymus. The
generation and subsequent analysis of reverse bone marrow chimeras (i.e. the reconstitu-
tion of irradiated Cers2gt/gt mice with wild type bone marrow (and CERS2 -deficient bone
marrow as control)) would be a simple way to verify this hypothesis. However, these exper-
iments could not be performed, as the CERS2 -deficient mice would most likely not survive
the rough irradiation procedure because of their limited viability (Figure 4.1 and [161]).
Another and more elegant way to test our assumption would be the specific deletion of
CERS2 in vascular endothelial cells. This would require the generation of a conditional
Cers2 knockout mouse (e.g. via flanking essential exons of the Cers2 gene with LoxP
sites) and the subsequent crossing with a vascular endothelial cell-specific driver line (e.g.
Tie2-Cre [222]).
Taken together, we discovered that CERS2 is a crucial factor for efficient S1P-mediated
thymic emigration of newly formed T cells into the periphery. On the basis of our data,
we propose a model, in which CERS2 in vascular endothelial cells maintains the thymic
S1P gradient and facilitates thymic exit by limiting the levels of S1P in the circula-
tion (Figure 5.1). By the identification of CERS2 as a novel factor of S1P-dependent thymic
egress, our study expands the knowledge on the maintenance of functional S1P gradients
in vivo and presents CERS2 as important regulator of peripheral T cell homeostasis and
thus of effective protection against invading pathogens.
5.2 CERS2 regulates S1P-mediated egress of circulating lymphocytes
from lymph nodes into efferent lymphatics
Apart from the regulation of emigration from the thymus into the blood, S1P gradients
also mediate the egress of circulating lymphocytes from lymph nodes into the efferent
lymphatics. Based on several studies, it is generally assumed that, like in the thymus,
the S1P gradients in the lymph nodes also result from low S1P levels in the parenchyma,
but high S1P levels at the cortical sinuses, which are the presumable exit sites into the
periphery [26]. Circulating lymphocytes enter lymph nodes as fully desensitized cells, which
is a consequence of the high S1P levels in the blood [15]. In response to the low S1P levels
75
5 DISCUSSION
Mature SP
Peripheral
T cell
Egress Desensitization
S1PR1
Thymus
Blood vesselEndothelial cell
VLC
cera
mide
s
Sphi
ngos
ine
S1P
Moderate S1P
production an export
Intact S1P gradient
S1PR1
Thymus
Blood vesselEndothelial cell
VLCceramides
Sphingosine
S1P
Increased S1P
production an export
Desensitization and 
impaired egress
Distorted S1P gradient
Wild type CERS2-deficient
S1P
S1P
Figure 5.1: Working model how CERS2 in vascular endothelial cells maintains the S1P gradient in the
thymus and facilitates efficient thymic egress of mature SP thymocytes into the circulation. The layout of
this figure is based on the graphics of [1, 59, 79].
in the lymph node parenchyma, however, they start to reexpress S1PR1 on their surface
while screening APCs for cognate antigens. After a dwell time of 6 - 24 hours without
beeing activated, the lymphocytes are completely resensitized and leave the lymph nodes
along the S1P gradient into the efferent lymphatics ([26] and 1.3.3). The importance of
S1P signaling for efficient emigration from lymph nodes was proven in various studies. For
instance, S1PR1-deficient lymphocytes, which had been adoptively transferred into wild
type recipients, readily accumulated in lymph nodes [17]. Moreover, specific ablation of
Sphks in lymphatic endothelial cells, which led to a reduction of lymph S1P and thus to a
disruption of the gradient, efficiently blocked lymph node egress [223]. Similar impairments
were observed after chemical inhibition of S1P lyase, which caused an elevation of the
S1P concentration inside the lymph nodes. Thus, the lymphocytes were desensitized and
eventually sequestered in the lymph nodes [102]. Likewise, treatment with FTY720, the
most prominent functional antagonist of S1PR1, also resulted in a robust desensitization
and a slowed emigation of lymphocytes from the lymph nodes into the efferent lymphatics,
which is the basis for the use of FTY720 as drug in the treatment of autoimmune diseases,
such as multiple sclerosis [107].
Consistent with an impaired egress from the thymus, Cers2gt/gt mice exhibited a robust T
cell lymphopenia in blood and spleen (Figure 4.6B and D). We observed, however, that the
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numbers of T cells in the lymph nodes were not affected by CERS2-deficiency (Figure 4.6F).
Concerning the important role of S1P signaling for lymph node egress and the newly iden-
tified function of CERS2 as potent regulator of S1P levels, we hypothesized that ablation
of CERS2 might not only impair emigration from the thymus, but also the S1P-dependent
reentry of circulating lymphocytes from the lymph nodes into the efferent lymphatics. Un-
der this assumption, the few T cells, which managed to overcome thymic sequestration
and started circulating through the periphery, will eventually be sequestered in the lymph
nodes. Thus, the peripheral T cell lymphopenia, which would normally affect all lymphoid
compartments to a similar extent, is masked in the lymph nodes and simultaneously ag-
gravated in blood and spleen. Importantly, as the entirety of all lymph nodes is a much
larger compartment than blood and spleen, an S1P-dependent redistribution of peripheral
lymphocytes is generally easier to detect by reduced lymphocyte counts in blood and spleen
than by an increased cellularity in individual lymph nodes, as it was discussed in the study
of Matloubian et al. [93]. As it was shown that plasma S1P does not contribute to the
S1P gradients in the lymphatic system, we expect that the impaired lymph node egress in
CERS2 -deficient mice is not caused by the elevated levels of S1P in the blood [26]. With
regard to the almost ubiquitous expression of CERS2 [155], however, it is quite possible
that absence of CERS2 in lymphatic endothelial cells or in the lymph node stroma might
lead to a local elevation of the S1P levels, which, in turn, desensitize the lymphocytes and
thus attenuate their exit into the efferent lymphatics. To verify this hypothesis, the gener-
ation and subsequent analysis of lymphatic endothelial cell-specific CERS2-deficient mice
would be an essential requirement (e.g. by using conditional Cers2 knockout mice and a
Lyve-1 driver line [103]). As already described for the mature SP thymocytes (see 5.1), the
putative desensitization of T cells in the lymph nodes of CERS2-deficient mice could also
be verified by measuring the surface levels of S1PR1. Moreover, a detailed quantification
of peripheral B cell populations in wild type and CERS2-deficient mice would also be of
interest, as the S1P gradients in the lymph nodes do not only mediate T cell but also B
cell egress into the efferent lymphatics [223].
Taken together, these findings suggest that CERS2 is not only important to regulate S1P-
mediated egress from the thymus, but also to facilitate S1P-dependent emigration of T
cells from the lymph nodes back into the circulation.
5.3 CERS2 is a multifunctional enzyme in basal sphingolipid metabolism
On a biochemical level, Cers2 is a key enzyme of sphingolipid anabolism, which generates
VLC (dihydro-)ceramides (mainly C24) by N-acylation of sphingoid bases with VLC fatty
acids. Interestingly, deficiency of CERS2, however, did not only lead to a loss of VLC sph-
ingolipids, but also to a compensatory increase in LC sphingolipids and an accumulation of
sphingoid bases [160, 166]. While VLC ceramides are generally regarded as protective and
anti-apoptotic lipids, LC ceramides and sphingoid bases are suspected lipotoxic mediators,
which promote cell stress or apoptosis [224, 225, 226]. Consequently, a working model was
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developed, in which CERS2 maintains physiological integrity by producing protective VLC
sphingolipids while simultaneously preventing the accumulation of cytotoxic LC ceramides
and sphingoid bases.
As mentioned before, we observed that CERS2-deficiency did not only lead to the ex-
pected alterations in the sphingolipid profile (loss of VLC SLs, increase of LC SLs and
accumulation of sphingoid bases), but also to robustly increased concentrations of S1P
in the thymus and in the blood, which distorted the chemotactic gradient and impaired
thymic egress of newly formed T cells into the circulation (see 4.1 and 5.1). Although we
cannot exclude that ablation of CERS2 affects the activity of the SPHKs via a regula-
tory feedback mechanism, we assume that the elevated S1P levels directly result from the
massive accumulation of sphingosine, which shifts the biochemical equilibrium to an en-
hanced S1P synthesis. This assumption is supported by the results of several other studies,
which investigated the physiological role of ceramidases and also demonstrated that the
amounts of sphingosine are a key determinant for the production of S1P [227]. It was,
for instance, shown that ablation of ACER3 (acid ceramides 3) leads to a decrease in the
levels of sphingosine and a concomittant reduction of S1P in the lungs [228]. Consistently,
overexpression of ACER1 (acid ceramidase 1) in HEK cells resulted in a co-elevation of
sphingosine and S1P [229]. The huge impact of sphingosine on S1P synthesis might in
particular be explained by the fact that the concentration of sphingosine is generally 100
fold higher than that of S1P. Thus, even small alterations in the levels of sphingosine can
have a strong effect on the production of S1P, which might not always be compensated by
counterregulatory mechanisms[114].
Importantly, correlations between the expression of CERS2 and the amounts of S1P were
already found in previous studies. Choi et al. found that increased levels of S1P were
associated with a reduced CERS2 expression in aged gastric smooth muscle cells [189].
Consistently, overexpression of CERS2 was sufficient to prevent an accumulation of S1P
in neurons, which lack CERS1 [190]. Nonetheless, physiological consequences for S1P-
dependent processes of a putative CERS2-S1P axis have not been analyzed in these studies.
Additionally, it should be noted that Liu and Pewzner-Jung et al. demonstrated that
ablation of CERS2-function had no effect on the levels of S1P in the liver, inspite of a
significantly increased concentration of sphingosine [166, 212]. Spatial differences in the
expression and/or activities of S1P degrading enzymes might be an explanation why the
absence of CERS2 can lead to an elevation of S1P in the blood (Figure 4.9) but not in
the liver. Generally, most tissues (not only the thymus) exhibit a low concentration of
S1P, which is, among other mechanisms, maintained by the activites of 6 different S1P-
degrading enzymes [26, 85, 89]. Consequently, the accumulation of sphingosine in CERS2 -
deficient livers might indeed lead to an enhanced S1P synthesis, but this could be readily
compensated by the superiority of the degrading enzymes. On the contrary, the blood
exhibits a high S1P concentration, which results from the low expression of S1P degrading
ezymes in circulating cells and the binding of S1P to carrier proteins, which are thought
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to provide protection from degradation [99, 218, 230]. Therefore, the elevated levels of
sphingosine in vascular endothelial cells of CERS2 -deficient mice might induce an increased
S1P production and export into the blood, where it is not efficiently degraded and can thus
accumulate (compare 5.1).
Taken together, by showing that ablation of CERS2 alters the levels of S1P and thus impairs
S1P-mediated lymphocyte egress, we demonstrate for the first time on a functional level
that CERS2 maintains physiological integrity not only by synthesizing VLC ceramides and
preventing the accumulation of LC sphingolipids and sphingoid bases, but also by limiting
the production of the potent lipid mediator S1P. Thus, our study adds a further facet to the
multifunctional character of CERS2. With regard to the magnitude of already identified
intra- and extracellular functions of S1P, such as regulating histon accessibility, controlling
the vascular tone or supporting growth, proliferation and differentiation (see 1.3.1), it might
be worthwhile to investigate if CERS2 is also important for other S1P-dependent processes
than lymphocyte trafficking.
5.4 The regulation of S1P-mediated thymic egress is a specific function
of CERS2
Although investigations on the pleiotropic functions of CERS2 still dominate the current
literature, the other members of the ceramide synthase family gained more and more
attention from the research community in the last years. Thus, several pioneering studies,
in which different CERS-deficient mouse models were analyzed, revealed that each CERS
has unique physiological functions. While it could be shown that CERS1 is important
for cerebellar development, it was found that CERS3 is crucial for cytokinesis during
male meiosis and for the maintenance of the skin barrier [158, 174, 175]. Studies of Ebel
and Peters at el. demonstrate that CERS4 is involved in the regulation of stem cell
homeostasis in the skin, hair follicle cycling and sebum composition [176, 177]. Moreover,
it was discovered that CERS5 and CERS6 play important roles in energy metabolism [167,
178].
Generally, this high degree of functional diversity has two reasons. First, all members of
the CERS family exhibit an individual expression pattern. CERS1, for example, is the
dominant CERS in the central nervous system and in skeletal muscles, but is absent in
most other tissues. Likewise, CERS3 is highly abundant in reproductive tissues, but close
to the detection limit in the rest of the organism [155].
Second, each CERS can only use fatty acids of a defined chain length for (dihydro-)ceramide
synthesis. Whereas CERS5 and CERS6, for instance, are restricted to the use of LC fatty
acids as substrates, CERS3 is limited to use VLC and ULC fatty acids [146]. Thus, each
CERS produces ceramides with different acyl chain lengths, which are known to have highly
specific cellular functions [225].
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Despite these differences, all ceramide synthases have in common that they use sphingo-
sine (and dihydrosphingosine) as substrate for the synthesis of (dihydro-)ceramides [129].
Consequently, we were interested if the consumption of sphingosine by other ceramide
synthases than CERS2 is also important for S1P production and thus for S1P-dependent
thymic egress (compare 5.1, 5.2 and 5.3). Importantly, a potential involvement of CERS1
and CERS3 was excluded a priori, as their expression is almost exclusively restricted to
tissues, which are most likely unimportant for the thymic S1P gradient, such as the central
nervous system, the skeletal muscles and the testes [155]. We hypothesized that CERS4
is the most probable candidate for having a similar impact on S1P-mediated egress pro-
cesses as CERS2, since it is, in contrast to CERS5 and CERS6, also highly expressed in
a variety of organs, tissues and cell types, which are known to be involved in the global
or local regulation of the thymic S1P gradient, such as the thymus, the liver or immune
cells in general (see 5.1 and [155]). Interestingly, we found that the thymic S1P gradient
and efficient egress of terminally differentiated thymocytes into the periphery were unaf-
fected in CERS4 -deficient mice, indicating that the consumption of sphingosine by CERS4
is not important for the regulation of S1P synthesis (see 4.3). Although CERS4 can be
found in various different tissues, its expression is mostly lower than that of CERS2 [155].
Therefore, we hypothesized that CERS4, in contrast to CERS2, is not abundant enough to
compete effectively with the SPHKs for sphingosine to influence the production of S1P in
cells, which are important for the maintenance of functional S1P gradients. Assuming that
the impact of CERS2 on the production of S1P exclusively depends on its high expression
levels, we moreover speculate that the consumption of sphingosine by CERS5 and CERS6
is presumably also not essential for the regulation of S1P synthesis, as both enzymes are
expressed on even lower levels than CERS4 in most tissues [155]. However, analyses of
CERS5- and CERS6-deficient mice need to be done in order to verify the this hypothesis.
Taken together, these findings suggest that the thymic S1P gradient is exclusively regu-
lated by CERS2 and not by any other CERS. Thus, our study further substantiates the
outstanding role of CERS2 within the ceramide synthase family.
5.5 CERS2 as putative pharmacological target
By identifying the impact of CERS2 on S1P gradients, our study present CERS2 as poten-
tial novel pharmacological target. Based on our findings, we hypothesize that administra-
tion of a CERS2 antagonist could mimick the sequestration of lymphocytes in lymphoid
organs, which is observed after FTY720 treatment, and might thus also be useful in the
medication of autoimmune diseases or other immunological disorders (see 1.3.3). Interest-
ingly, a chemical inhibitor that selectively targets CERS2 and not the other members of
the CERS family was already characterized in an in vitro study of Schiffmann et al. [231].
However, as it is known from Cers2gt/gt mice that the organism-wide ablation of CERS2
can lead to serious phenotypes, the main challenge of targeting CERS2 for clinical pur-
poses will be to avoid severe secondary effects [160, 161, 166]. Delivery strategies, which
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target only the specific cell types/tissues/organs of interest and not the whole organism are
absolutely required to address this issue, as they are currently developed for other critical
drugs, such as anti-cancer agents [232].
5.6 Concluding remarks on the role of CERS2 in early T cell develop-
ment in female mice
The thymus is of fundamental importance for adaptive immunity, as it provides a unique
microenvironment, which is required for T cell development [27]. In the course of thymic
T cell development, bone marrow-derived ETPs (early thymic progenitors) are induced by
thymic stromal cells to undergo several steps of differentiation and proliferation, in which
they stochastically rearrange the segments of their β- and α-chains to diversify the TCR
repertoire, on the one hand, and become committed to the CD4 or the CD8 lineage, on
the other hand. After the cells with non-functional (unable to recognize peptide:MHC
complexes) or autoreactive TCRs have been filtered out by extensive selection procedures,
the remaining thymocytes, which express functional and self-tolerant TCRs, are allowed
to complete thymic T cell development, enter the circulation and become part of the
peripheral T cell pool, which protects the organism from invading pathogens (see 1.2).
Surprisingly, we observed that ablation of CERS2 led to a significant reduction in thymic
cellularity in female mice, but not in males (Figure 4.2). Although this reduction was de-
tectable in all thymocyte subsets, cells of the DN1 stage were affected the most (Figure 4.17).
Interstingly, several independent studies revealed that thymic involution, the age-dependent
reduction in thymic mass, cellularity and output, is partially mediated by sex hormones [28,
233, 27, 234, 235]. It could, for instance, be shown that androgen ablation (i. e. castration)
in aged mice and rats is sufficient to regenerate a fully functional thymus [236, 237, 238].
Consistently, it was found that estrogen-treated mice exhibit a reduction of thymic cellular-
ity by 80% [239]. Strikingly, it was demonstrated in studies of Heng and Zoller et al. that
sex hormones limit thymic cellularity predominantly by impairing T cell differentiation
already at the ETP/DN1 stage and not by inducing apoptosis in later stages [239, 240].
With regard to the female-specific reduction in thymic cellularity in Cers2gt/gt mice and
the huge impact of sex hormones on early T cell development, we assume that CERS2-
deficiency interferes with the estrogen-dependent control of thymic involution. We specu-
late that the reduced numbers of ETPs and the atrophic thymi in female Cers2gt/gt mice
are either caused by an increased production of estrogen in the ovaries or by defects in
estrogen-receptor signaling in the thymus. In support of the first speculation is a study by
Pieper et al, in which it was demonstrated that downregulation of CERS2 stimulates the
secretory pathway (vesicle trafficking at the ER-Golgi interface) in chinese hamster ovary
cells (CHO) [241]. Consequently, it is conceivable that deficiency of CERS2 might also
amplify vesicle trafficking in the ovaries and thus lead to an enhanced estrogen secretion.
In sum, these findings indicate that CERS2 regulates thymic T cell development not only
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by facilitating the egress of terminally differentiated T cells along the S1P gradient, but
most likely also by preventing a premature estrogen-induced thymus involution. However,
the verification of a potential involvement of CERS2 in the regulation of hormone-driven
processes warrants further investigations, first of all quantifications of estrogen levels in
female (and male) CERS2-deficient mice.
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6 Summary
A key element for effective adaptive immunity against invading pathogens is an ever-
changing peripheral TCR repertoire, which requires the constant release of newly formed
T cells from the thymus. The process of thymic egress into the circulation is of chemo-
tactic nature and is mediated by a soluble gradient of the lipid mediator sphingosine-1-
phosphate (S1P), which results from low S1P levels in the thymic interstitium, but high S1P
levels at the thymic exit sites and in the blood. Despite its importance for peripheral T cell
homeostasis, the exact architecture of the thymic S1P gradient, as well as the underlying
mechanisms, which maintain the spatial differences in S1P concentration are incompletely
understood.
In the present study, we investigated if ceramide synthase 2 (CERS2), as regulator of the
S1P precursor sphingosine, is involved in the maintenance of the thymic S1P gradient.
We found that CERS2 -deficient mice not only exhibited increased amounts of sphingo-
sine, but also elevated levels of S1P within the thymic parenchyma, in the plasma and
in RBCs, which resulted in a robust distortion of the S1P gradient between thymus and
blood. Consistently, thymic egress was impaired in CERS2 -deficient mice, indicated by
a selective accumulation of egress-competent mature SP thymocytes in the thymus and
a corresponding T cell lymphopenia in the periphery. We, therefore, concluded that the
CERS2-dependent regulation of sphingosine is an important mechanism to facilitate ef-
ficient thymic egress of newly formed T cells into the periphery, as it prevents aberrant
S1P synthesis by the sphingosine kinases (SPHKs) and thus stabilizes the chemoattrac-
tive S1P gradient between thymus and blood. CERS2 is ubiquitously expressed in the
hematopoietic and non-hematopoietic cells of the thymus. However, we observed that
neither the exclusive ablation of CERS2 in hematopoietic cells, nor the specific absence
of CERS2 in thymic stromal cells could phenocopy the impaired S1P-dependent thymic
egress, which was observed in CERS2 -deficient mice. These results indicate that CERS2
shapes the thymic S1P gradient not by regulating S1P production in the thymus itself, but
in extrathymic non-hematopoietic cells and thus exclusively by limiting the levels of S1P in
the circulation. Based on our CERS2 expression data and the current understanding how
S1P levels in blood are regulated, we hypothesize that vascular endothelial cells are the
most promising cell type, in which CERS2 might be required to compete with the SPHKs
to limit the production and secretion of S1P into the plasma.
Taken together, our study establishes for the first time a requirement of CERS2 for S1P
gradient regulation between thymus and blood. Thus, we advance the understanding
how egress from primary lymphoid organs and peripheral lymphocyte homeostasis are
regulated in vivo. Consequently, CERS2 might be a promising pharmacological target to
treat autoimmune diseases or other immunological disorders by manipulating lymphocyte
trafficking.
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